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Abstract 
Heterologous immunity is a mechanism by which immunological memory 
within an individual, developed in response to a previous infection, plays a role in 
the immune response to a subsequent unrelated infection. In murine studies, 
heterologous immunity facilitated by cross-reactive CD8 T-cell responses can 
mediate either beneficial (protective immunity) or detrimental effects (e.g. 
enhanced lung and adipose immunopathology and enhanced viral titers) (Selin et 
al., 1998; Chen et al., 2001; Welsh and Selin, 2002; Nie et al., 2010; Welsh et al., 
2010).  Protective heterologous immunity results in enhanced clearance of virus 
during a subsequent infection with an unrelated pathogen.  Such is the case 
when mice are immunized with lymphocytic choriomeningitis virus (LCMV) and 
subsequently challenged with Pichinde virus (PV) or vaccinia virus (VACV) (Selin 
et al., 1998).  However, heterologous immunity may also mediate enhanced 
immunopathology as mice immunized with influenza A virus (IAV) and 
challenged with LCMV show increased viral titers and enhanced lung 
immunopathology (Chen et al., 2003).   
The role heterologous immunity plays during infection is not limited to the 
murine system.  In fact, there have now been several reports of enhanced 
immunopathology due to heterologous immunity during human infections, 
involving viruses such as IAV, Epstein-Barr Virus (EBV), hepatitis C virus (HCV), 
and dengue virus (DENV) (Mathew et al., 1998; Wedemeyer et al., 2001; Acierno 
et al., 2003; Nilges et al., 2003; Clute et al., 2005; Urbani et al., 2005).  
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Interestingly, in all reported cases in humans, heterologous immunity mediated 
enhanced immunopathology.   
Upon infection with EBV the clinical presentation can range from 
asymptomatic to severe, occasionally fatal, acute infectious mononucleosis  
(AIM) (Crawford et al., 2006b; Luzuriaga and Sullivan, 2010) which is marked by 
a massive CD8 lymphocytosis.  This lympho-proliferative effect in AIM was 
shown to be partially mediated by reactivation of cross-reactive IAV-M158-66 (IAV-
GIL) specific CD8 memory T-cells in HLA-A2 patients reacting to the EBV-
BMLF1280 (EBV-GLC) epitope (Clute et al., 2005). 
Interestingly, EBV infects ~90% of individuals globally by the third decade 
of life, establishing a life-long infection (Henle et al., 1969).  However, it is 
unknown why 5-10% of adults remain EBV-sero-negative (EBV-SN), despite the 
fact that the virus infects the vast majority of the population and is actively shed 
at high titers even during chronic infection (Hadinoto et al., 2009). Here, we show 
that EBV-SN HLA-A2+ adults possess cross-reactive IAV-GIL/EBV-GLC memory 
CD8 T-cells that show highly unique properties. These IAV-GIL cross-reactive 
memory CD8 T-cells preferentially expand and produce cytokines to EBV 
antigens at high functional avidity.  Additionally, they are capable of lysing EBV-
infected targets and show the potential to enter the mucosal epithelial tissue, 
where infection is thought to initiate, by CD103 expression.  This protective 
capacity of these cross-reactive memory CD8 T-cells may be explained by a 
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unique T-cell receptor (TCR) repertoire that differs by both organization and 
CDR3 usage from that in EBV-seropositive (EBV-SP) donors.   
The composition of the CD8 T-cell repertoire is a dynamic process that 
begins during the stochastic positive selection of the T-cell pool during 
development in the thymus.  Thus, upon egress to the periphery a naïve T-cell 
pool, or repertoire, is formed that is variable even between genetically identical 
individuals.  This T-cell repertoire is not static, as each new infection leaves its 
mark on the repertoire once again by stochastically selecting and expanding 
best-fit effectors and memory populations to battle each new infection while at 
the same time deleting older memory CD8 T-cells to make room for the new 
memory cells (Selin et al., 1999).  These events induce an altered repertoire that 
is unique to each individual at each infection. It is this dynamic and variable 
organization of the T-cell repertoire that leads to private specificity even between 
genetically identical individuals upon infection with the same pathogens and thus 
a different fate (Kim et al., 2005; Cornberg et al., 2006a; Nie et al., 2010).  It is 
this private specificity of the TCR repertoire that helps explain why individuals 
with the same epitope specific cross-reactive response, but composed of 
different cross-reactive T-cell clones, can either develop AIM or never become 
infected with EBV. 
Our results suggest that heterologous immunity may protect EBV-SN 
adults against the establishment of productive EBV infection, and potentially be 
the first demonstration of protective T-cell heterologous immunity between 
ix
unrelated pathogens in humans.  Our results also suggest that CD8 T-cell 
immunity can be sterilizing and that an individual’s TCR repertoire ultimately 
determines their fate during infection. 
To conclusively show that heterologous immunity is actively protecting 
EBV-SN adults from the establishment of a productive EBV infection, one would 
have to deliberately expose an individual to the virus.  Clearly, this is not an 
acceptable risk, and it could endanger the health of an individual.  A humanized 
mouse model could allow one to address this question.   
However, before we can even attempt to address the question of 
heterologous immunity mediating protection from EBV infection in humanized 
mice, we must first determine whether these mice can be infected with, and build 
an immune response to the two viruses we are studying, EBV and IAV.  We 
show here that these mice can indeed be infected with and also mount an 
immune response to EBV.  Additionally, these mice can also be infected with 
IAV.  However, at this time the immune responses that are made to these viruses 
in our established humanized mouse model are not substantial enough to fully 
mimic a human immune response capable of testing our hypothesis of 
heterologous immunity mediating protection from EBV infection. 
Although the immune response in these mice to EBV and IAV infection is 
not suitable for the testing of our model the data are promising, as the humanized 
mouse model is constantly improving.  Hopefully, with constant improvements 
xbeing made there will be a model that will duplicate a human immune system in 
its entirety. 
This thesis will be divided into 5 major chapters.  The first chapter will 
provide an introduction to both general T-cell biology and also to the role of 
heterologous immunity in viral infection.  The second chapter will provide the 
details of the experimental procedures that were performed to test our 
hypothesis.  The third chapter will describe the main scientific investigation of the 
role of heterologous immunity in providing natural resistance to infection in 
human subjects.  This chapter will also consist of the data that will be compiled 
into a manuscript for publication in a peer-reviewed journal.  The fourth chapter 
will consist of work performed pertaining to the establishment of a humanized 
mouse model of EBV and IAV infection.  The establishment of this model is 
important for us to be able to show causation for protection from EBV infection 
mediated by heterologous immunity. 
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1Chapter I: Introduction 
Memory CD8 T-cells are an important mediator of resistance to re-
infection by previously encountered pathogens, primarily viruses (Welsh et al., 
2004).   After viral clearance the activated effector CD8 T-cell pool begins its 
contraction phase and formation of a stable memory pool.  Memory CD8 T-cells 
in general are superior to naïve CD8 T-cells, as they have the ability to recognize 
cognate peptide-MHC (pMHC) in the peripheral tissues and exert effector 
functions, while naïve CD8 T-cells that see cognate pMHC without proper 
costimulation signals undergo peripheral tolerization (Redmond and Sherman, 
2005).  As compared to naïve CD8 T-cells, memory CD8 T-cells are maintained 
at a higher frequency due to their previous clonal expansion, mediated by IL-7 
and IL-15 with the help of CD4 cells, and can be maintained without the need for 
antigen (Surh and Sprent, 2008). Memory CD8 T-cells are also rapidly activated 
due to an open chromatin structure from the previous activation, require less 
antigen to become activated, and show a varied tissue distribution (Arens and 
Schoenberger, 2010).  Therefore, being maintained at a higher frequency than 
naïve CD8 T-cells with the ability to exert rapid effector function in response to a 
lower level of antigen puts memory CD8 T-cells at an advantage when 
challenged with a recognizable pMHC antigen 
Over the years it has become evident that CD8 T-cells can recognize 
more than one antigen.  If a CD8 T-cell can be cross-reactive and recognize 
more than one antigen, and a memory CD8 T-cell is at an advantage over naïve 
2CD8 T-cells, then it stands to reason that a memory CD8 T-cell exposed to a 
cross-reactive epitope from an unrelated virus would preferentially become 
activated over a naïve CD8 T-cell.  This is indeed the case as our lab has 
demonstrated this phenomenon in both murine and human systems and found it 
to be a common occurrence (Welsh et al., 2010; Selin et al., 2011).  Of the 
several cross-reactive responses that have been identified there appear to be 
consequences resulting from them.  In the murine system one of the resulting 
consequences is partial protection, where prior immunity to one virus results in a 
lower viral titer when challenged with an unrelated virus as compared to naïve 
controls (beneficial).  Another consequence is that of immune-pathology following 
challenge with an unrelated virus that is distinct from naïve controls challenged 
with the same virus (detrimental).  This phenomenon of altered immunity 
resulting from cross-reactive CD8-T-cells has been coined heterologous 
immunity.   
Detrimental heterologous immunity has also been described during human 
infections.  The reports of heterologous immunity and cross-reactive CD8 T-cells 
in humans have coincided with enhanced pathology such as dengue shock 
syndrome during DENV infection, necrotizing fulminant hepatitis during HCV 
infection, and AIM during EBV infection where IAV-GIL specific memory CD8 T-
cells were shown to cross-react with EBV-GLC peptide (Mathew et al., 1998; 
Wedemeyer et al., 2001; Acierno et al., 2003; Nilges et al., 2003; Clute et al., 
2005; Urbani et al., 2005).  Although there are no direct descriptions of beneficial 
3protective heterologous immunity in humans there is some epidemiological 
evidence that shows children vaccinated with live measles virus (MV) vaccine or 
Bacille-Calmette-Guerin (BCG) have unexpectedly lower morbidity and mortality 
to other pathogens than those not vaccinated (Aaby et al., 1995; Stensballe et 
al., 2005; Farrington et al., 2009). 
The goal of this thesis was to determine if heterologous immunity and 
cross-reactive CD8 T-cells could mediate protection from viral infection in 
humans.  To determine whether heterologous immunity and cross-reactive CD8 
T-cells were mediating protection from viral infection we used EBV as our 
infection model.  Previously our lab had identified a cross-reactive CD8 T-cell 
response between IAV and EBV.  This cross-reactivity was between the HLA-A2 
restricted epitopes IAV-GIL and EBV-GLC and was found not only to occur 
during AIM but also contribute to lymphoproliferation associated with AIM (Clute 
et al., 2005).  Subsequently, we have also identified an additional cross-reactivity 
between IAV and EBV this time mediated again by IAV-GIL but cross-reacting 
with EBV-BRLF1 (EBV-YVL) (Aslan et. al. unpublished data).  We questioned 
whether these same cross-reactive patterns between IAV and EBV were capable 
of mediating protection from EBV infection.  To do this we examined EBV-SN 
adults and assessed their cross-reactive patterns compared to that of EBV-SP 
adults.  Additionally, we also examined the T-cell receptor (TCR) repertoire within 
the EBV-SN adults to determine whether there were any unique features that 
might explain why the same cross-reactive epitopes lead to AIM in some 
4individuals while protecting others from infection.  We also set out to establish a 
humanized mouse model of viral infection so as to recapitulate our finding in a 
testable model. 
This introduction is separated into two major sections.  The first section is 
an overall description of T-cell immunity.  The second half more specifically 
pertains to the biology of heterologous immunity. 
1. T-cell Immunity: 
A. Generation of the CD8 T-cell pool 
The generation of a highly diverse CD8 T-cell receptor (TCR) repertoire 
within an individual is started by somatic rearrangement of the germline encoded 
V-, D-, and J-regions within the tcrb locus and V- and J-regions of the tcra locus 
(Taghon and Rothenberg, 2008).  Mathematically it is theorized that there can be 
up to 1015 different TCR heterodimer pairs in mice. Though following negative 
and positive thymic selection which results in a massive die off of cells that either 
can not react to pMHC (positive selection) or react to strongly pMHC (negative 
selection) the actual number is estimated to be in the area of 106-108, much 
lower than theorized (Arstila et al., 1999; Casrouge et al., 2000; Nikolich-Žugich 
et al., 2004). The complementarity determinant regions (CDRs), CDR1 and 
CDR2, within the V region of the TCR have natural affinity for the major 
histocompatibility complex (MHC) molecule, while the CDR3, the region covering 
the somatic rearrangement, recognizes peptide bound to the MHC (pMHC) 
(Huseby et al., 2005; Dai et al., 2008). 
5T-cells develop in the thymus where they undergo a process known as 
positive selection.  Cells that can bind the MHC with low affinity survive the 
process by receiving survival signals, while cells that cannot bind the MHC 
undergo death by neglect (Starr et al., 2003).  At this stage of development T-
cells express both CD4 and CD8 and are referred to as double positive (DP) 
thymocytes.  DP thymocytes that have a lower affinity for pMHC-I, lose CD4 
expression and retain CD8 expression, while DP thymocytes with a higher affinity 
for pMHCII retain the expression of CD4.  This later results in the expression of 
the CD4 lineage commitment transcription factor ThPOK (Singer et al., 2008; 
Collins et al., 2009). 
DP thymocytes that survive positive selection go on to negative selection.  
During this process thymocytes that demonstrate high affinity binding to self 
pMHC are selectively deleted by receiving signals to undergo apoptosis 
(Hogquist et al., 2005).  This selection event results in the deletion of cells that 
could cause autoimmune disease in the host if they were allowed access to the 
periphery.   
After thymocytes finish negative selection they leave the thymus and 
become recent thymic emigrants with a naïve phenotype of CD62Lhigh, CCR7high, 
CD44low, and CD24+ (Tough and Sprent, 1994).  As they migrate through the 
secondary lymphoid tissues they increase the levels of their markers slightly and 
lose CD24 expression to become mature naïve T-cells (Makaroff et al., 2009).  In 
humans naïve T-cells have a half-life of 4-6 years and require IL-7 for their 
6survival (Link et al., 2007; Vrisekoop et al., 2008).  An additional necessity for 
survival of CD8 T-cells is interaction with self-pMHC-I in the periphery (Tanchot 
et al., 1997; Polic et al., 2001; Surh and Sprent, 2008; Takada and Jameson, 
2009). 
The MHC-I heavy chains are a set of 3 separate genes all of which are 
highly polymorphic.  These molecules present small peptides derived primarily 
from proteins synthesized within the cell.  The high degree of polymorphism is 
manifest within the peptide-binding groove of the MHC-I (Trowsdale, 2005).  This 
alteration of the binding groove results in variations in the anchor residues 
responsible for peptide binding and consequently a more diverse peptide pool.  
With the combination of a highly diverse peptide pool and a highly diverse TCR 
repertoire CD8 T-cells can recognize virtually any foreign protein. 
B.  T-cell Activation 
Activation of T-cells by ligation of TCR/pMHC results in an array of downstream 
signaling events.  The first event is the activation of the src family of protein 
tyrosine kinases (PTKs), primarily lck (Samelson et al., 1986; Straus and Weiss, 
1992).  These kinases then phosphorylate the homo- and hetero-dimeric CD3-
ζ, -ε, -δ, and -γ proteins within their immune-receptor tyrosine-based activation 
motifs (ITAMs).  These phosphorylation events then result in the recruitment of 
the CD3 ζ associated protein of 70kDa (ZAP-70) which subsequently activates 
the trans-membrane adapter protein linker for the activation of T-cells (LAT) by 
phosphorylation. ZAP-70 also recruits and activates the cytosolic adapter protein 
7Src homology 2 (SH2) domain-containing leukocyte phosphoprotein of 76kDa 
(SLP-76) by phosphorylation (Bubeck Wardenburg et al., 1996; Zhang et al., 
1998).  The recruitment of these two molecules builds the backbone of the 
signaling complex by organizing the signaling effector molecules in the correct 
spatiotemporal order to begin the multiple signaling cascades (Smith-Garvin et 
al., 2009). 
When LAT becomes phosphorylated and activated by ZAP-70 it then 
recruits the kinases phospholipase C-γ-1 (PLCγ-1) and phosphoinositide 3-
kinase (PI3K).  Additionally, it recruits the adapter molecules growth factor 
receptor-bound protein 2 (GRB2) and GRB2-related adapter downstream of Shc 
(Gads) (Sommers et al., 2004).  SLP76 is then recruited to LAT by their mutual 
binding partner Gads and itself recruits Vav1, Nck, IL-2-induced tyrosine kinase 
(Itk), adhesion and degranulation-promoting adapter protein (ADAP) and 
hematopoietic progenitor kinase 1 (HPK1).  SLP76 also binds to PLCγ-1, which 
has already been recruited to LAT (Koretzky et al., 2006).  While LAT and SLP76 
mediate the nucleation of the signaling complex, the effector molecules that are 
recruited help to stabilize the complex (Reynolds et al., 2002; 2004; Dombroski et 
al., 2005).  The LAT/SLP76 complex ultimately results in the activation of PLCγ-1 
which hydrolyses phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) to inositol 
1,4,5-triphospate (IP3) and diacyl glycerol (DAG).  The release of IP3 to the 
cytosol results in release of Ca2+ from the endoplasmic reticulum (ER), which in 
turn activates Ca2+-release activated Ca2+ (CRAC) channels to produce a flux in 
8Ca2+ (Lewis and Cahalan, 1995).  This increase in Ca2+, coupled with DAG 
mediated activation of protein kinase C (PKC) (which also activates NFκB), 
results in the activation and translocation to the nucleus of NFAT where it is free 
to associate with AP-1 and induce transcription of target genes, most notably IL-2 
(Ullman et al., 1990; Jain et al., 1995; Karin et al., 1997).   
The increase in Ca2+ flux is also linked to cytoskeleton restructuring 
(Burkhardt et al., 2008).  Cytoskeleton restructuring is an important part of T-cell 
activation, as treatment with actin polymerization inhibitors impedes T-cell/APC 
interaction and proper signaling (Henney and Bubbers, 1973; Holsinger et al., 
1998).  One of the primary events in the cytoskeleton restructuring is the 
polarization of the microtubular organizing complex toward the TCR/pMHC 
contacts (Kupfer et al., 1987).  This event is crucial for the formation of the 
immunological synapse (IS) where TCR and costimulation signals are thought to 
be amplified (Cemerski et al., 2008; Yokosuka et al., 2008).  Also there is a 
formation of the distal pole complex which may be important for shuttling away 
inhibitory regulatory factors from the IS (Burkhardt et al., 2008) and also may 
contribute to the polarization of signaling molecules responsible for memory 
versus effector fate decisions (Chang et al., 2007).  These signaling events are 
summarized in figure 1.1. 
In addition to TCR engagement and signaling there is also a need for 
costimulation to ensure proper T-cell activation.  The best characterized of the 
costimulation molecules is CD28.  Signaling through CD28 ultimately results in
9Figure 1.1 Schematic diagram of TCR signaling showing the separate arms and
players involved. The first panel depicts the links between adapter protein tyrosinekinases involved in the initial signaling events and the downstream events of Ca++ flux andRas activation. The bottom two panels represent events involved in Ras activation andCa++ flux. Figure adapted from Smith-­‐Garvin et. al. T-­‐cell Activation. Annu. Rev. Immunol.27, 591-­‐619 (2009)
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 the activation of Akt which is responsible for many activities, most notably NFκB 
activation and IL-2 production (Acuto and Michel, 2003; Narayan et al., 2006; 
Qiao et al., 2008).  In addition to CD28 there are other molecules involved in 
costimulation.  Inducible costimulator (ICOS) is a molecule which is related to 
CD28 and performs many of the same functions, but it is not involved in IL-2 
production, and it is not constitutively expressed (Hutloff et al., 1999; Coyle et al., 
2000).  Two additional costimulation molecules in the TNF receptor family are 
41BB and OX40, which both result in enhanced Akt and NFκB activation.  While 
CD28 and ICOS are important for activation, 41BB and OX40 seem to be 
important for memory formation (Watts, 2005). 
In contrast to costimulation there are also important negative regulators of 
TCR signaling.  Both CD45 and SH2 domain-containing protein tyrosine 
phosphatase (SHP1) are phosphatases which act to limit the phosphorylation 
state of the signaling complex (Hermiston et al., 2003; Stefanová et al., 2003).  
Two additional inhibitory molecules, cytotoxic T lymphocyte antigen-4 (CTLA-4) 
and programmed death-1 (PD-1), are involved in dampening TCR signaling and 
have been shown to recruit and activate SHP1.  Mice with either of these 
molecules deleted develop autoimmunity (Waterhouse et al., 1995; Nishimura et 
al., 2001).  CTLA-4 has the added property of binding to the CD28 ligands CD80 
and CD86 with a high affinity potentially sequestering them away from the 
costimulation molecule. 
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Up to this point I have been discussing CD4 and CD8 T-cells 
interchangeably.  Although CD4 cells are very important players in the immune 
system the rest of this dissertation will focus on CD8 T-cells. 
C. Acquisition of Effector Functions and Memory Formation 
Naive CD8 T-cells survey the body for infection by migrating to secondary 
lymphoid tissues and sampling antigen presenting cells (APCs), primarily 
dendritic cells (DCs), for their cognate antigen.  During an infection naïve CD8 T-
cells first come into contact with primed antigen bearing DCs within the sub-
capsular sinus or the interfollicular region of the draining lymph node (LN) 
(Hickman et al., 2008; John et al., 2009).  Under non-inflammatory conditions 
antigen recognition results in anergy or peripheral tolerance, but in the context of 
inflammation or infection antigen recognition from an APC results in a clonal 
expansion and rapid acquisition of effector functions by antigen specific T-cells 
(Steinman et al., 2003; Masson et al., 2008; Arens and Schoenberger, 2010).  
After clonal expansion and at the peak of the primary CD8 T-cell response there 
is a heterogeneous population of short lived effector cells (SLEC) defined by 
KLRG1+ CD127- which mostly die off during contraction, and a population of 
memory precursor effector cells (MPEC) defined by a KLRG1- CD127+ 
phenotype which go on to form the memory pool (Mescher et al., 2006; Parish 
and Kaech, 2009).  Single cell transfer studies have shown that a single naïve 
CD8 T-cell can differentiate into a diverse population of both effector and 
memory cells (Stemberger et al., 2007; Gerlach et al., 2010), although this 
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phenomenon has been questioned as naïve CD8 T-cells with differing amounts 
of interferon-γ (IFN-γ) transcript have been shown to maintain their differing 
transcript levels even after many rounds of division (Beuneu et al., 2010).  
Another observation during initial CD8 T-cell activation is the phenomenon of 
asymmetric cell division that ultimately results in an unbalanced segregation of 
protein degradation machinery and the T-box transcription factor T-bet between 
the two daughter cells (Chang et al., 2011).  Since it is known that an increased 
amount of T-bet forces CD8 T-cells to be more of a SLEC (Badovinac et al., 
2007a) it is thought that this asymmetric division results in a differing lineage 
decision (Chang et al., 2007).  This idea has been questioned as CD8 T-cells 
with signaling deficiencies have been shown to split T-bet evenly and still 
develop MPECs (Smith-Garvin et al., 2010). 
For a single naïve CD8 T-cell to undergo many rounds of division with one 
division occurring every 2-6 hours (Yoon et al., 2010) there would have to be a 
large need for nutrients.  It has been shown that with antigen priming CD8 T-cells 
enhance the uptake of nutrients like glucose, amino acids, and iron and also 
switch from oxidative phosphorylation to aerobic glycolysis (Vander Heiden et al., 
2009; Michalek and Rathmell, 2010).  CD28 costimulation and activation of 
mammalian target of rapamycin (mTOR) is responsible for this metabolic shift 
(Macintyre et al., 2011).  More recently it has been thought that Erk signaling 
may also contribute (Carr et al., 2010; Marko et al., 2010). 
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To attain maximal clonal expansion naïve CD8 T-cells need to receive 
signals 1 (TCR/pMHC engagement), 2 (CD28 costimulation), and 3 
(inflammatory cytokine stimulation) (Zhang and Bevan, 2011).  The inflammatory 
cytokine IL-12 effectively promotes effector cell differentiation through mTOR-
dependent T-bet induction (Takemoto et al., 2006; Badovinac et al., 2007a; Rao 
et al., 2010).  It was originally thought that IL-2 was the major player in clonal 
expansion based on in vitro studies.  However, recent in vivo studies have noted 
that clonal expansion upon initial naïve T-cell priming is only slightly decreased in 
CD8 T-cells that lack the high affinity IL-2 receptor CD25, but they do show 
functional and phenotypic alterations (Williams et al., 2006; Bachmann et al., 
2007).  These CD25 KO effectors trended towards an MPEC and T-central 
memory (Tcm) phenotype with increased CD62L and CD127 and decreased 
KLRG1.  Recently, it has become more apparent that IL-2 may be more 
important for terminal effector cell generation.  It has been shown that activated 
CD8 T-cells cultured in the presence of high IL-2 concentrations acquire superior 
effector functions and that CD8 T-cells deficient in CD25 are defective in killing 
ex vivo with a decrease in granzyme B and perforin expression (Carrio et al., 
2004; Pipkin et al., 2010).  In general CD8 T-cells are CD25high during early 
infection, but by day 3.5-5 the effector pool starts to take on a bimodal 
distribution, with CD25high cells expressing higher KLRG1 and granzyme B and 
lower CD62L and IL-2 expression (Kalia et al., 2010).  The end of the peak of the 
CD8 T-cell response brings on the contraction phase.  CD8 T-cells with a SLEC 
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phenotype that lack CD25 show a drastic decline during contraction as compared 
to WT SLECs (Mitchell et al., 2010) suggesting that IL-2 is important for the 
maintenance of SLECs during the contraction phase.  Additionally, it has been 
shown that low IL-2 signaling results in CD62Lhi memory cells (Decaluwe et al., 
2010).  These data hint that IL-2 will be found to be important for the 
maintenance of CD62L- CCR7- effector memory cells (TEM). 
IL-2 signaling through CD25 results in the activation of the transcriptional 
repressor Blimp-1, the protein product encoded by the Prdm1 gene, which in turn 
creates a negative feedback loop by inhibiting IL-2 production (Malek and Castro, 
2010).  Blimp-1 is primarily expressed by SLECs and decreases as memory is 
formed (Kallies et al., 2009; Rutishauser et al., 2009).  Blimp-1’s higher 
association with effector cells is consistent with the fact that there is a higher 
level of Blimp-1 expression during chronic infections (Shin et al., 2009).  Prdm1-/- 
CD8 T-cells exhibit normal clonal expansion, but there is a defect in their effector 
functions and SLEC differentiation (decrease in granzyme B, perforin, and 
KLRG1) resulting in an increase in MPEC markers (increase of CD127, CCR7, 
CD62L, CD27, and IL-2) (Rutishauser et al., 2009; Zhang and Bevan, 2011).  
These Prdm-/- CD8 T-cells also have a decrease in exhaustion markers PD-1, 
LAG3, CD160, and 2B4 during chronic infection (Shin et al., 2009).  Figure 1.2 
illustrates effector T-cell generation. 
After there has been sufficient activation and expansion of the effector 
subsets the effectors need to leave the secondary lymphoid tissue and enter the
15
Figure 1.2. Effector T-­‐cell generation. Naïve T-­‐cells seeing their antigen inaddition to costimulation and in an inflammatory environment differentiate intoeffector cells. After antigen clearance some effector cells (SLECs) undergoapoptosis while some effector cells (MPECs) go on to form the memory pool.Duration of antigen exposure has consequences on effector function as longexposure results in exhaustion with high apoptosis and little to no memory poolformation. Adapted from Arens, R & Schoenberger, S. P. Plasticity in programingof effector and memory CD8 T-­‐cell formation. Immunol. Rev. 235, 190-­‐205(2010)
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 peripheral tissues.  This entry into peripheral tissues is mediated by an up 
regulation of the chemokine receptor CXCR3 (Groom and Luster, 2011).  It is 
believed that CD8 cells are recruited to the sites of infection by CXCL9 and 
CXCL10 expressed by epithelial cells that have been activated by CD4 effector 
cells which have arrived previously and secreted IFNγ in the area of infection 
(Bevan, 2004; Nakanishi et al., 2009).  Interestingly, after arriving at the site of 
infection in the periphery effector CD8 T-cells continue to undergo antigen-
specific interactions that drive further proliferation and cytokine release (McGill 
and Legge, 2009; Bedoui and Gebhardt, 2011).  This phenomenon appears to 
require the recruitment of monocyte-derived DCs which continue to present 
antigen and costimulation signals (Hufford et al., 2011). 
While CD8 T-cell recognition of cognate antigen and engagement of 
effector function at the site of infection are  very important aspects of immunity, 
they create a highly inflammatory environment, which could cause collateral 
damage to surrounding tissues.  Some interesting observations have been made 
lately that suggest that CD8 T-cells may self-regulate by producing the immune-
suppressive cytokine IL-10 to help limit this collateral damage.  CD8 T-cells have 
been shown to produce IL-10 at the site of infection, but IL-10+ CD8 T-cells 
disappear after the infection is controlled (Sun et al., 2009; Palmer et al., 2010; 
Trandem et al., 2011; Zhang and Bevan, 2011).  These IL-10+ CD8 T-cells at the 
site of infection are generally better killers with higher levels of granzyme B, 
IFNγ, and TNFα.  Additionally these IL-10+ CD8 T-cells do not appear to be a 
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different lineage of effector cell, just a transient reversible state that seems to 
wane after antigen is cleared (Trandem et al., 2011).  This IL-10 production is 
activated by a combination of IL-2 from CD4 effector cells and IL-27 from an 
innate cell, most likely a neutrophil.  Blimp has also been found to be essential 
for IL-10 induction (Sun et al., 2011).  Strong and continuous TCR/MAPK 
signaling may be important for this IL-10 production as many IL-10+ CD8 T-cells 
are also CD69+, suggesting recent TCR stimulation, and this ability to produce IL-
10 seems to revert after viral clearance (Trandem et al., 2011). 
After viral clearance the activated effector CD8 T-cell pool begins its 
contraction phase and formation of a stable memory pool.  Memory CD8 T-cells 
in general are superior to naïve CD8 T-cells.  As compared to naïve CD8 T-cells, 
memory CD8 T-cells are maintained at a higher frequency due to their previous 
clonal expansion, mediated by IL-7 and IL-15 with the help of CD4 cells, and can 
be maintained without the need for antigen (Surh and Sprent, 2008). Memory 
CD8 T-cells are also rapidly activated due to an open chromatin structure from 
previous activation and are no longer restricted to peripheral blood and 
secondary lymphoid tissues as they can enter peripheral tissues (Arens and 
Schoenberger, 2010). 
The CD8 memory cells that survive the contraction phase are divided into 
two general groups know as TEM and TCM.  These two groups are based on their 
phenotypic expression of CD62L and CCR7, two molecules that are required for 
entry into the high endothelial venule of the secondary lymphoid organs (Sallusto 
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et al., 1999).  TEM cells are defined by their low expression of CD62L and CCR7 
and primarily reside in the peripheral tissues while TCM have high expression of 
these two molecules and are primarily found within, and circulating to, lymphoid 
organs, but both can be found in the blood and spleen (Sallusto et al., 1999; 
Masopust et al., 2001).  These two populations of memory cells also vary in their 
mediation of effector functions.  TEM cells have the ability to produce effector 
functions such as cytotoxicity much more rapidly than their TCM counterparts, but 
their ability to proliferate is markedly decreased as compared to TCM cells.  
Conversely, TCM have an increased ability to proliferate when they encounter 
their antigen as compared to TEM.  A complication to the field is the debate of 
whether TEM and TCM cells are distinct lineages or whether they can undergo 
inter-conversion.  Independent laboratories have shown conflicting results.  
When a physiological level of naïve precursors are primed during an infection it 
appears that there is seldom TEM to TCM conversion, but when there are a higher 
level of precursors TEM are able to convert to TCM (Wherry et al., 2003; Badovinac 
et al., 2007b; Sarkar et al., 2007).  Other groups also suggest that TCM cells are 
able to convert to TEM (Huster et al., 2006; Marzo et al., 2007). 
Both of these populations have protective capacity when re-exposed to 
pathogen, but the context of the infection is what determines their protective 
ability.  For instance, a peripheral VACV infection requires a TEM population for 
protection while a systemic LCMV infection requires TCM (Wherry et al., 2003; 
Bachmann et al., 2005). 
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D. CD8 T-cell Immunity to EBV 
EBV infects 95% of the world population and is essentially ubiquitous 
(Henle et al., 1969).  Infection occurs by salivary contact, and the virus 
establishes infection in cells within the oropharynx (Hislop and Sabbah, 2008).  
The initially infected cell type is unclear but it is probably an epithelial cell or B-
cell residing in the oropharynx.  Productive infection results in the establishment 
of latent infection and long term shedding of the virus and is established in B-
cells that have been transformed by the virus.  Latent viral proteins induce cell 
proliferation and replication of the episomal viral genome.  The genome is 
maintained in memory B-cells, which transit between blood and oropharyngeal 
tissue where the virus can reactivate to the lytic cycle and resume viral shedding 
and infect additional B-cells (Laichalk et al., 2002). 
EBV has been associated with many malignancies of B-cells and epithelial 
cells such as Burkett’s lymphoma, Hodgkin’s lymphoma, and nasopharyngeal 
carcinoma.  EBV has also been associated with post transplant lymph-
proliferative disorder (PTLD).  Each of these malignancies expresses a differing 
repertoire of viral proteins that could be used as targets for therapeutic 
intervention (Hislop and Sabbah, 2008). 
Primary infection can result in asymptomatic infection or AIM, which is 
characterized by pharyngitis and lymphadenopathy, but can range from mild 
symptoms to very severe disease with splenomegaly, hepatomegaly, and even 
result in death.  Within the adolescent and young adult population 25% of primary 
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infections result in AIM, and, although it is rare, young children have been 
reported to come down with AIM (Chan et al., 2003; Crawford et al., 2006b).  The 
marked expansion of CD8 T-cells during AIM was at one point thought to be 
mediated by a superantigen, as a selective expansion of Vβ6.1-3 and Vβ7 CD8 
T-cells resembled that of a S. aureus enterotoxin B mediated expansions (Smith 
et al., 1993).  This extensive Vβ restricted CD8 T-cell activation has now been 
shown to be primarily antigen specific, as only certain clones within the Vβ6.1-3 
and Vβ7 families were expanded and shown to react to EBV antigens (Callan et 
al., 1996; Maini et al., 2000).  Additionally, the majority of the activated CD8 T-
cells were found to be antigen specific by tetramer and intra-cellular cytokine 
staining for IFNγ (Callan et al., 1998; Hoshino et al., 1999; Catalina et al., 2001; 
Hislop et al., 2002).  The CD8 T-cell response reacts to both lytic and latent 
epitopes at the height of the disease.  Initial studies limited their investigation to 
peptide epitopes from the EBNA3 family and LMP2 family and concluded that 
they accounted for the majority of the CD8 T-cell response (Steven et al., 1996), 
but we now know that they account for only about 3% of the response (Hislop et 
al., 2002).  The major contributors of epitopes are the lytic proteins (Steven et al., 
1997; Callan et al., 1998; Catalina et al., 2001; Hislop et al., 2002; Woodberry et 
al., 2005b; Cameron et al., 2006) with the immediate early proteins BZLF1 and 
BRLF1 encoding peptides across a range of HLA alleles.  There are also strong 
T-cell responses to the early proteins, such as BMLF1, but only to a subset of 
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these viral products that are expressed early during infection (Pudney et al., 
2005). 
Upon resolution of the acute symptoms the expanded CD8 T-cell effector 
pool shrinks with the contraction of EBV-specific responses (Catalina et al., 2001; 
Hadinoto et al., 2007).  An interesting but un-deciphered observation is the 
differing levels of contraction of the different antigen-specific populations within 
the expanded CD8 T-cell pool, with antigen-specific populations that had a high 
frequency completely retracting while low level populations survive (Hislop et al., 
2002).  For example EBV-YVL, an epitope derived from a lytic protein, is 
immune-dominant during primary infection yet retracts to near depletion in the 
resolved infection, while EBV-CLG, an epitope derived from the latent protein 
LMP2, is absent from primary infection yet dominates in convalescence. 
The activated EBV-specific CD8 T-cells show an effector phenotype with 
up-regulation of CD38 and CD45RO, while being in cycle and showing cytolytic 
capabilities (Callan et al., 2000; Catalina et al., 2002; Dunne et al., 2002; Hislop 
et al., 2002; Soares et al., 2004).  Again the lytic versus latent protein reactive 
CD8 T-cells show differing characteristics.  Lytic protein reactive CD8 T-cells 
show a down-regulation of co-stimulation markers CD27 and CD28 while latent 
protein reactive CD8 T-cells show intermediate expression of these molecules 
(Soares et al., 2004).  There is also a switch back to CD45RA expression on the 
lytic protein reactive CD8 T-cells while the latent protein reactive CD8 T-cells 
retain CD45RO expression (Catalina et al., 2002; Hislop et al., 2002).  It has also 
22
been shown that lytic reactive cells are more resistant to apoptosis, are not in 
cycle, and can be easily reactivated (Dunne et al., 2002).  It is unclear why this 
occurs.  It may be that the CD8 T-cells reactive against lytic epitopes are a more 
central memory cell and have not seen antigen since the initial infection, while 
the CD8 T-cells recognizing the latent epitopes are continually exposed to 
antigen and are in more of an effector state. 
Most EBV studies are performed on samples that have come from the 
peripheral blood.  However, lytic replication and B-cell transformation will most 
likely occur at the oropharyngeal epithelial surfaces or nearby lymphoid tissues 
(Pegtel et al., 2004).  Therefore, tonsillar tissues will be particularly informative.  
During infection there appears to be a poor recruitment of lytic reactive cells into 
the tonsillar tissues whereas latent reactive cells appear to be in the tonsil at 
similar proportions as in the blood (Hislop et al., 2005).  After resolution of 
infection 20% of the CD8 T-cells in the tonsil are reactive to EBV and there 
appears to be a 10-fold increase in latent reactive cells and a 3-fold increase in 
lytic reactive cells as compared to the blood, with most expressing CD103, an 
integrin required for entry into mucosal epithelial tissues (Hislop et al., 2005; 
Woodberry et al., 2005a). 
The question still remains why do some people get AIM and others appear 
to be asymptomatic?  Some findings have suggested that polymorphisms in the 
IL-10 promoter result in an altered outcome of disease (Helminen et al., 1999).  
One allele that resulted in higher levels of IL-10 production was found to correlate 
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with EBV-SN adults and patients with asymptomatic disease.  The other allele, 
which results in lower IL-10 production, correlated with the occurRance of AIM 
and highly correlated with severe symptoms.  Our group has shown that 
heterologous immunity and CD8 T-cell cross-reactivity between IAV and EBV 
may mediate increased pathology (Clute et al., 2005). 
E.  Characteristics of IAV infection and HLA-A2 restricted immunodominant 
IAV-GIL response 
Most of the world’s population has been infected with IAV while very 
young and have virus-specific memory CD8 T-cells.  IAV-specific memory T-cells 
can comprise 0.06-1.6% of the CD8 T-cell pool found in the blood as determined 
by whole virus stimulation (Boon et al., 2002; He et al., 2003).  After primary 
infection an increase in the number of CD8 T-cells can be found in the peripheral 
blood between days 6-14 post infection returning to baseline 21-28 days after 
infection (Wright, 2001).  The CD8 T-cell response is known to target all the viral 
proteins, but the immunodominant response is mediated against matrix 1 (M1), 
the most abundant viral protein and most highly conserved (Gotch et al., 1987; 
Man et al., 1995; Jameson et al., 1998).  All individuals who are HLA-A2 positive 
present and mount an immunodominant response to IAV-M158-66 (IAV-GIL) 
(Gotch et al., 1987; Bednarek et al., 1991; Lehner et al., 1995; Lalvani et al., 
1997; Lawson et al., 2001; Pittet et al., 2001).  The frequency of IAV-GIL 
restricted cells averages out to about 0.1% of the CD8 T-cells in the blood 
(Lehner et al., 1995; Lalvani et al., 1997; Jameson et al., 1998; Pittet et al., 
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2001).  By making point mutations in the IAV-GIL peptide it was determined that 
the central portion of the peptide was important for its recognition by IAV-GIL 
specific T-cells.  When the crystal structure of IAV-GIL bound to HLA-A2 was 
solved it was evident that IAV-GIL was unusual, as the amino acid (aa) side 
chains did not face the TCR with the AA backbone facing the solvent (Madden et 
al., 1993).  Perhaps this structure would require the TCR to interact with more of 
the MHC rather then the generic solvent exposed backbone.  It is possible that 
this unique structure is responsible for the IAV-GIL TCR repertoire being 
restricted primarily by Vβ 19 Jβ 2.7 and Vα 27 Jα 42 while having an x-arginine-
serine-x (xRSx) CDR3β motif and a CDR3α that consists of multiple glycines 
(Moss et al., 1991; Lehner et al., 1995; Naumov et al., 1998; Lawson et al., 
2001).  The IAV-GIL/HLA-A2/TCR crystal structure revealed that the TCR bound 
to the pMHC in a unique fashion (Stewart-Jones et al., 2003).  As opposed to the 
previously solved crystal structures where TCR/pMHC interactions show 
diagonal binding of the TCR, the IAV-GIL reactive TCR binds perpendicular to 
the pMHC.  Additionally, the IAV-GIL specific CD8 TCR was found to 
predominantly use the CDR3β to cover the peptide rather than a 50:50 split with 
the CDR3α.  Despite the dominant selection for Vβ 19 and Vα 27 the repertoire 
can be described as polyclonal.  Many Vβ 19 clones exist based on nucleotide 
sequences that encode the xRSx motif (Naumov et al., 2006).  There are also 
clones that express different Jβ families resulting in variability in the length of the 
CDR3 loop (Naumov et al., 2006).  By maintaining a large clonal distribution the 
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immune system is better able to adapt to any changes in the properties of the 
ligand over time and thus decrease the chances of developing viral escape 
mutants (Naumov et al., 2006).  
2. Heterologous T-cell Immunity 
A. Definition of Heterologous Immunity 
Heterologous immunity can be broadly defined as the impact of immunity 
from a previous infection on the outcome of a subsequent unrelated infection.  
Thus each new infection we experience is potentially influenced by our past 
histories of infection. The concept was first described to help explain the 
differences observed in protective immunity and immunopathology in C57Bl/6 
mice that had been immunized with one virus and later challenged with another 
virus anywhere from 6 weeks to 2 years later (Selin et al., 1998; Chen et al., 
2001; 2003).  This heterologous immunity was ultimately found to be mediated by 
cross-reactive T-cells (Brehm et al., 2002; Kim et al., 2005; Cornberg et al., 
2010a; Nie et al., 2010)(Chen et. al. in press Plos Pathogen).  However, there 
may be other mechanisms contributing to heterologous immunity such as 
macrophage activation by bacterial infection creating a short lived protection from 
other bacteria (Mackaness, 1964).  There is also the concept of original antigenic 
sin, which suggests that previous exposure to one strain of IAV diverts the 
antibody response after exposure to a second IAV strain to epitopes that are 
shared between the two strains (Fazekas de St Groth and Webster, 1966). 
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Heterologous immunity may not be as effective as homologous immunity, 
but it can help to facilitate a much attenuated infection as measured by 
decreased viral loads and increased survival rates from lethal dose (Selin et al., 
1998; Chen et al., 2001; Nie et al., 2009).  Using an adoptive transfer of immune 
splenocytes it was originally observed that both CD4 and CD8 T-cells were 
required for mediating protective immunity in LCMV immune mice challenged 
with VACV (Selin et al., 1998).  However, a selective expansion of some, but not 
all, LCMV epitope-specific CD8 T-cells during a vaccinia virus infection 
suggested that cross-reactive CD8 T-cell responses were responsible (Chen et 
al., 2001; Kim et al., 2002).  It was later found that these cells are responsible for 
mediating protective heterologous immunity by the reduction of viral titers 
(Cornberg et al., 2010a). 
Heterologous immunity can be beneficial by mediating partial protective 
immunity, but it can also lead to detrimental immunity that can manifest itself as 
greatly enhanced immunopathology, higher viral loads, or increased morbidity 
and mortality (Selin et al., 1998; Walzl, 2000; Chen et al., 2003).  These 
differential effects likely occur through multiple different mechanisms.  One 
possible mechanism is the activation of lower avidity cross-reactive memory CD8 
T-cells which may hamper the development of a new cognate high avidity CD8 T-
cell response from naïve precursors (Selin et al., 2011).  A high avidity agonist 
(cognate peptide) TCR interaction induces full activation potential of a CD8 T-cell 
including proliferation, cytokine production, and cytotoxicity.  A low avidity partial 
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agonist (cross-reactive peptide) TCR interaction requires approximately 10-100 
fold more ligand to induce similar effector functions (Sloan-Lancaster and Allen, 
1996; Hemmer et al., 1998; Kersh et al., 1998; Ding et al., 1999; Zehn et al., 
2009).  Low avidity TCR interactions may also produce different cytokines, 
altered cytokine amounts, or could be less cytolytic or proliferative (Selin et al., 
2011).  Recent studies have found that CD8 T-cells responding to low affinity 
partial agonist peptides initially undergo clonal expansion at the same rate as 
CD8 T-cells undergoing activation by agonist interactions; however, the CD8 T-
cells responding to the partial agonist leave the lymph node sooner and lose 
sustained expansion, causing them to eventually be out competed by agonist 
reactive CD8 T-cells (Zehn et al., 2009).  These differences in reactivity to 
agonist and partial agonist peptide are most likely related to differences in TCR 
signal strength perhaps mediated by ITAM usage.  Developmental studies have 
shown that negative selection is influenced by the number and specificity of the 
TCR-CD3 ITAMS activation state, suggesting that the TCR is capable of scalable 
signaling (Holst et al., 2008).  
B.  Examples of heterologous immunity in a murine infection model 
One of the first models developed that identified heterologous immunity 
was LCMV-immune C57Bl/6 mice challenged with VACV.  From this 
experimental induction of heterologous immunity there was an observation of 
both partial immune protection, as measured by a 2-log reduction in viral titer, 
and also some induction of immunopathology, as exhibited by paniculitis of the 
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visceral fat (Yang et al., 1985; Selin et al., 1998).  VACV was shown to activate 
LCMV-specific memory CD8 T-cells specific to the LCMV epitope NP205 (Chen et 
al., 2001).  Based on these results the VACV proteome was screened for 
sequence homology to LCMV NP205, and peptide sequences from two viral 
proteins, e7r and a11r, were found (Welsh et al., 2004; Cornberg et al., 2006b; 
2010a).  Both VACV epitope-specific responses provide protection to VACV 
infection, but only one, a11r, was cross-reactive with LCMV NP205 (Cornberg et 
al., 2006b; Moutaftsi et al., 2009).  Interestingly, the expansion of LCMV NP205 
specific memory CD8 T-cells cells due to VACV infection occurred only half of 
the time, while the other half of the time other LCMV-specific responses were 
expanding, including GP34 and GP118 which are Kb restricted (Kim et al., 2005; 
Cornberg et al., 2010a).  In fact, there are multiple cross-reactive CD8 T cell 
responses in LCMV-immune mice infected with VACV. VACV infection 
sometimes expands LCMV NP205-specific T cells, but other times LCMV GP34- or 
GP118-specific T cells expand upon adoptive transfer of LCMV-immune 
splenocytes into naïve mice (Kim et al., 2005).  This variability in responses is not 
due to random stochastic events but instead reflects the private specificity of the 
LCMV-immune T cell repertoire in individual mice.  This was demonstrated by 
adoptive transfer of LCMV immune splenocytes into 3 recipients from the same 
donor, which was shown to generate the same specificity of outgrowth of LCMV 
epitope-specific T cells.  However, recipients of splenocytes from a different 
donor demonstrate a different specificity. These results indicate that the private 
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specificities of the LCMV memory T-cell population dictate which cross-reactive 
epitope would be recognized. 
This cross-reactivity between LCMV and VACV has proven to provide 
partial protective immunity.  Interestingly, many immunizing viruses provide 
partial protective immunity to VACV infection including LCMV, PV, IAV, and 
MCMV, and also the bacterium BCG (Selin et al., 1998; Chen et al., 2001; 2003; 
Mathurin et al., 2009).  It is proposed that the cross-reactive T-cells that are 
mediating this protection.  CD8 T-cell lines generated from LCMV-immune mice 
and stimulated with a11r peptide were transferred into naïve mice and 
challenged with VACV.  Transfer of cell lines which demonstrated the most 
functional cross-reactive response, as measured by EC50, a measure of 
functional avidity, to both LCMV and VACV epitopes, resulted in the greatest 
level of protective immunity based on VACV titers (Cornberg et al., 2010a).   
One aspect left to determine is what type of cross-reactive response leads 
to beneficial protective versus harmful detrimental heterologous immunity.  One 
potential mediator of these differences is differential production of cytokines to 
the cross-reactive ligands.  It has been shown that IFNγ can be responsible for 
both partial protection and immunopathology (Selin et al., 1998; Chen et al., 
2001).  Additionally, it is known that TNFα is responsible for mediating paniculitis 
but not partial protection in a LCMV-immune VACV infection model (Selin et al., 
2011).   
30
In order to examine a more natural route of infection an intra-nasal 
infection model was used.  Mice were immunized with LCMV and subsequently 
challenged with VACV.  This model also showed partial protection by reduction in 
viral loads and altered immunopathology in the lung (Chen et al., 2001; 2003).  
Again, pathologies did vary from mouse to mouse consistent with the idea of 
private specificity. 
A second model of heterologous immunity in the murine system is that of 
LCMV immune mice challenged with the distantly related PV.  This model 
preferentially shows partial protection, as LCMV immune mice present with a log 
lower viral titer without significant immune-pathology (Selin et al., 1998; Brehm et 
al., 2002).  The heterologous immunity associated with this model has been 
shown to be mediated by cross-reactive CD8 T-cells, more specifically LCMV 
NP205 reactive cells recognizing PV NP205, as immunization with a LCMV NP205 
mutant virus did not mediate protection (Cornberg et al., 2006a)(Chen et. al. 
2012). 
The two NP205 cross-reactive peptides have 6 of 8 amino acids in common 
and only differ in the MHC anchor site (Brehm et al., 2002).  As seen in the 
overlaid crystal structure the overall conformations of the LCMV- NP205 and PV- 
NP205 peptides bound to H2Kb are similar.  The respective H2Kb binding clefts 
adopt similar conformations with the largest difference in a specific region of the 
α2-helix.  The presence of the tyrosine hydroxyl group in position 5 of the LCMV 
peptide, instead of the phenylalanine found in the PV peptide, accounts for this 
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perturbation of the α2-helix (Chen et. al. in press Plos Pathogens).  Most of the 
CD8 T-cells that are generated to one NP205 epitope will recognize the other but 
with differing binding affinities as suggested by differing tetramer staining 
patterns (Cornberg et al., 2006a).  Surprisingly, the TCR repertoire usage 
between these two epitope specific populations is quite different.  LCMV NP205 
almost exclusively uses Vβ 16 while PV NP205 uses Vβ 5 and Vβ 16, and the Vβ 
CDR3 region is very different from that usually seen in LCMV NP205 response 
(Cornberg et al., 2006a).  The perturbation of the α2-helix most likely accounts 
for the differing TCR repertoire.  The TCR repertoire that is available for cross-
reactive expansions is established during the first infection and is unique 
between individuals and accounts for private specificity (Cornberg et al., 2006a; 
Selin et al., 2011).  During the second infection a narrow subset of the antigen 
specific CD8 T-cell memory pool is stimulated to proliferate when exposed to the 
cross-reactive antigen (Haanen et al., 1999; Cornberg et al., 2006a).  Infections 
with these two heterologous viruses, encoding very similar cross-reactive 
epitopes, induce a high frequency of an oligo-clonal set of T-cell clones that 
dominate the CD8 T-cell response.  This results in a narrowing of the LCMV/PV 
NP205 restricted TCR repertoire (Cornberg et al., 2006a; Selin et al., 2011). 
Heterologous immunity and CD8 T-cell cross-reactivity are frequently not 
reciprocal.  For instance, mice that have been immunized with VACV and then 
re-challenged with LCMV, PV, IAV, or MCMV demonstrate no protective 
32
immunity or increased immunopathology (Selin et al., 1998).  This may be due to 
differences in the private specificity of the TCR repertoire. 
These data taken together begin to show a pattern or network of cross-
reactive T-cell responses to the epitopes encoded by LCMV, PV, and VACV as 
shown in figure 1.3.  It is these networks of cross-reactivities that are the 
underlying mediators of heterologous immunity.  Additionally, it is also the private 
specificity of the response to this network of cross-reactivities that determines 
one’s fate when encountering a new infection (Kim et al., 2005; Cornberg et al., 
2010b). 
The final murine model of heterologous immunity I will discuss is that of a 
respiratory intra-nasal (i.n.) model of IAV-immune mice challenged with LCMV.  
In this model there are increased virus titers and greatly enhanced pathology.  
This infection is characterized by massive lung pathology demonstrating 
consolidating mononuclear pneumonia and bronchiolization instead of a mild 
lymphocytic pneumonitis commonly seen during intranasal LCMV infection (Chen 
et al., 2003).  It was found that the increased viral titers were dependent on IAV-
specific memory CD4 T-cells and the increased immunopathology was 
dependent on IAV-specific memory CD8 T-cells.  IAV-PB1703- and -PA224 specific 
cells were cross-reactive with LCMV-GP34 and –GP276 (Wlodarczyk et. Al. 
unpublished data).  These two populations were found to be the mediators of the 
pathology. IAV strains with these epitopes mutated, peptide tolerization of IAV-
PB1703- and -PA224 specific memory cells (Redmond et al., 2005), or anti-IFNγ 
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therapies alleviated the enhanced pathologies.  These two IAV epitopes, IAV-
PB1703- and -PA224, could potentially be thought of as “pathogenic” epitopes. 
These results strongly support the usefulness of studying heterologous immunity 
in order to develop new therapies to prevent viral immunopathogeniesis and 
improve vaccine design. 
C.  Heterologous immunity during human infection 
Ultimately we as scientists want our work to translate to a better 
understanding of human disease to help advance human health. However, 
studying disease directly in humans can be very difficult and at times frustrating, 
due to ethical considerations and patient non-compliance. 
The study of protective beneficial heterologous immunity in humans can 
be particularly difficult, as a protective effect would more than likely go unnoticed. 
However, the study of enhanced immunopathology during human infection is 
easier than studying protective immunity because of its overt nature.  If cross-
reactive T cell responses are harmful to the host, their influence on the outcome 
of an infection may become more evident, perhaps resulting in an altered 
disease state.  Some infections have very different pathological outcomes 
perhaps being mediated by differences in the private specificity of their TCR 
repertoire.  These infections provide strong hints as to where one could 
investigate the roles of heterologous immunity.  Some specific examples include 
viral infections such as EBV with the associated disease AIM where it is more 
severe in young adults than in younger children.  Another example is the 
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variation in pathology within HCV infected patients.  Some patients that acquire 
HCV infection are capable of clearing the infection.  Within others the disease 
progresses to a chronic state where the virus is never cleared, and pathologies 
range from asymptomatic to fulminant necrotizing hepatitis and even death.  
Another example of an infectious disease with differing symptoms is dengue 
virus (DENV) infection.  Interestingly, all of these infections have had CD8 T-cell 
cross-reactive responses associated with their course of disease, as I will 
discuss below. 
DENV is divided up into four distinct serotypes (DENV 1-4) (Halstead, 
1989; Morens, 1994) which serologically cross-react but do not provide 
neutralizing antibody.  DENV has also been shown to encode variable CD8 T-cell 
epitopes that cross-react between the sero-types (Spaulding et al., 1999; Zivny et 
al., 1999; Mongkolsapaya et al., 2003; Bashyam et al., 2006; Beaumier et al., 
2008).  DENV infection can cause a wide array of disease presentations ranging 
from asymptomatic upward to dengue fever, dengue hemorrhagic fever, and 
dengue shock syndrome.  The more severe forms of the disease occur when an 
individual is first infected with one serotype and then later infected with an 
alternate serotype.  This phenomenon was originally thought to be mediated by 
non-neutralizing antibodies binding virus and delivering the virus to Fc receptor 
bearing cells, a process known as antibody-dependent enhancement (Halstead, 
1989), but this may be only a portion of the phenomenon.  It is believed that 
heterologous immunity and cross-reactive CD8 T-cells are contributing to this 
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pathology as well (Mathew et al., 1998).  It has been found that cross-reactive 
memory CD8 T-cells responding to the second DENV infection have a higher 
avidity to the primary antigen than the secondary antigen.  These cross-reactive 
cells expand at the expense of the secondary cognate epitope-reactive cells and 
mediating pathology (Mongkolsapaya et al., 2003; Friberg et al., 2011).  One of 
the important implications of these studies is that there may be a problem 
designing a pan-dengue serotype vaccine since primary DENV infection 
ultimately results in an increased possibility for pathogenesis upon subsequent 
cross-serotype infection. 
A second example of CD8 T-cell cross-reactivity comes from the field of 
hepatitis C virus.  Many HCV sero-negative individuals have reactivity against the 
HCV HLA-A2 restricted epitope HCV-NS31073 and a portion of the CD8 T-cells 
reactive to this epitope cross-react with an IAV-epitope, IAV-NA231 (Wedemeyer 
et al., 2001). While most HCV patients with mild disease have a diverse CD8 T-
cell pool recognizing epitopes across the HCV proteome, two patients that 
developed a CD8 T-cell response that was highly focused to only this cross-
reactive HCV-NS31073 epitope developed a rare fulminant necrotizing hepatitis 
upon HCV infection (Urbani et al., 2005).  This example of human heterologous 
immunity and cross-reactive CD8 T-cells is similar to the murine system in that 
there appears to be private specificity as only a portion of patients developed this 
focused detrimental cross-reactive response and adverse immunopathology. 
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Heterologous immunity also may play a role during EBV infection.  EBV is 
a gamma herpes virus that infects up to 95% of the population.  It falls into the 
category of viral infections that are more severe in young adults, who 
theoretically have  more experienced large complex T-cell memory populations 
due to previous viral exposures, than in young children.  EBV infection in younger 
children usually results in an asymptomatic response. Infection in young adults 
more often results in acute infectious mononucleosis (AIM), which can vary 
greatly in severity from mild pharyngitis and lymphadenopathy, to severe 
hepatomegaly, splenomegaly, and even death.  The main characteristic of AIM is 
an acute lymphocytosis consisting primarily of activated CD8 T-cells.  These cells 
are often referred to as atypical lymphocytes, which are cytotoxic lymphocytes 
(CTLs) responding to infected B-cells and epithelial cells of the oropharynx.  
There is no evidence of increased viral load in AIM patients as compared to 
asymptomatic patients (Silins et al., 2001).  Therefore the major pathological 
feature of AIM is a massive CD8 T-cell response.  Our group has shown that 
HLA-A2 positive AIM patients have an increase in IAV-GIL reactive CD8 T-cells 
and that these cells are cross-reactive with the EBV-GLC peptide in some 
individuals (Clute et al., 2005).  Recently, our group has found that IAV-GIL 
specific cells can also be cross-reactive to another lytic EBV epitope EBV-BRLF1 
(EBV-YVL) and, interestingly, that EBV-YVL and EBV-GLC responses also show 
intra-viral cross-reactivity (Cornberg et al., 2010b).  Additionally, we have 
observed a direct correlation between the frequency of cells cross-reactive 
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between IAV-GIL/EBV-GLC and the severity of AIM, while EBV viral load does 
not correlate (Aslan et. al. unpublished data) suggesting that this particular cross-
reactive response is important in mediating the severity of AIM (Fig 1.4).  IAV-
GIL and EBV-GLC have only three of nine amino acids in common, and IAV-GIL 
and EBV-YVL share only one amino acid.  Interestingly, the TCR repertoire of 
these cross-reactive cells in AIM patients is devoid of highly dominant clonotypes 
as compared to the non-cross-reactive repertoire and is in fact rather broad 
(Clute et al., 2010).  This may be explained by less similar epitopes not having 
any high affinity clones which might dominate and narrow the response as 
appears to happen with more similar cross-reactive epitopes as described earlier 
(Cornberg et al., 2006a).  
In addition to the cross-reactive responses seen between IAV-GIL and 
EBV-GLC and –YVL we have noted other cross-reactive responses between 
these two viruses that also occur, but less frequently.  These include inter-viral 
cross-reactive responses between EBV-GLC and influenza B virus (IBV) IBV-
NP85 (IBV-KLG) and also between IAV-GIL and EBV-EBNA3a596 (EBV-SVR), 
and also intra-viral cross-reactive responses between EBV-GLC and EBV-YVL 
and EBV-GLC also reacting to EBV-LMP2329 (EBV-LLW).  Again these cross-
reactive patterns begin to form networks of cross-reactivity between the antigen 
specific responses, and each individual will have a different cross-reactive 
pattern, based on the private specificity of their TCR repertoire.  Thus the private 
specificity of each individual’s TCR repertoire will determine their reaction to 
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these antigens and will ultimately decide the outcome of the infection (Kim et al., 
2005; Cornberg et al., 2010b) (Fig 1.5). 
These data taken together suggest that heterologous immunity and cross-
reactive CD8 T-cells may be a common event during human infections.  
Additionally, these data further help explain the variability in disease outcome 
that is seen between individuals infected with the same pathogen often 
previously attributed to host genetics, pathogen dose and physiological 
conditions of the host.   
On the other hand studying protective beneficial heterologous immunity in 
humans can be particularly difficult as a protective effect would more than likely 
go unnoticed.  To study this one must rely on epidemiological studies.  One such 
study found that BCG or live measles vaccine offered decreased mortality to 
rotaviral diarrhea and other infectious pneumonias in African children (Aaby et 
al., 1995; Stensballe et al., 2005; Farrington et al., 2009).  Interestingly, 
subsequent vaccination with killed diphtheria, pertussis, and tetanus vaccine 
(DPT) can reverse these beneficial effects and also increase mortality (Aaby et 
al., 2007; Benn et al., 2009). 
An additional case where heterologous immunity may be mediating 
protection is the case of Kenyan female sex workers who are consistently HIV 
sero-negative despite the fact that they are continuously exposed to the virus 
(Fowke et al., 1996).  Intriguingly, this protection waned if the individuals left the 
trade (Jennes et al., 2006).  This may indicate that constant exposure may be a
41
 
Fi
gu
re
1.
5.
Th
e
ne
tw
or
k
of
cr
os
s-­‐
re
ac
ti
vi
ty
se
en
in
EB
V
in
fe
ct
io
n.Sum
maryo
fthecr
oss-­‐rea
ctiven
etwork
s
seenw
ithinH
LA-­‐A2+
individ
ualsbe
tween
EBVan
dIAV.
Directi
onofa
rrowin
dicates
amem
orypop
ulation
capabl
e
ofresp
onding
tothe
epitope
.Arrow
thickne
ssisa
relative
indicat
orofd
etectio
nfrequ
ency.N
umber
sinbr
ackets
indicat
ethen
umber
oftime
sthec
ross-­‐re
active
respon
sewas
detecte
dand
thenu
mbero
fpatie
ntstha
twere
examin
ed.
42
 protective factor.  Interestingly, there has been a report of cross-reactive CD8 T-
cells amongst HIV sero-negative individuals between IAV-GIL (IAV-M158-66) and 
HIV-gp17-GAG77-85 (Acierno et al., 2003).  Perhaps this is what is mediating 
protection from HIV infection. 
D.  The use of humanized mice to study human infection 
Due to the limitations in conducting research on humans there is a need 
for the development of an animal model, which can mimic human immunity.   The 
model of humanized mice may be able to fill this gap.  Humanized mice are mice 
that have either had human genetic elements transgenicly inserted into their 
genome or mice that have received an implantation of human tissues.  The first 
model of human cell implantation in mice came in 1983 with the discovery of a 
severe combined immunodeficiency (SCID) mutation in CB17 mice.  Human 
hematopoietic cells were able to engraft in these mice, but engraftment levels 
were low primarily because of high levels of NK cells (Shultz et al., 2011).  Later, 
SCID mice were crossed to non-obese diabetic (NOD) mice and these mice 
exhibited enhanced engraftment due to decreased levels of NK cells (Shultz et 
al., 2007; 2011).  The next major step forward was the cross of NOD/SCID mice 
to IL2 receptor common gamma chain knockout (IL2rγnull) mice to create 
NOD/SCID IL2rγnull (NSG) mice.  These mice showed even greater engraftment 
of human hematopoietic cells and also development of a fully functional human 
immune system when engrafted with hematopoietic stem cells (HSC) (Shultz et 
al., 2007).  While there are other base models of humanized mice, this model 
43
seems to provide the best engraftment.  Importantly, there are even more 
improvements being made onto this base model.  Two in particular are the 
development of mice expressing the human MHC molecule HLA-A2 and a model 
that incorporates fetal human tissues.  One of the caveats of the NSG model is 
the lack of a human MHC molecule for CD8 T-cell selection.  By crossing the 
NSG mice to an HLA-A2 transgenic mouse CD8 T-cell development is improved.  
Figure 1.6 summarizes the history of the development of the humanized mouse 
model.  Even more critical for the proper development of T-cells is the presence 
of human thymic tissue.  In the BLT (bone marrow, liver, and thymus) mouse 
model NSG-HLA-A2 transgenic mice have had fetal organs placed under the 
kidney capsule followed by injection of HSCs.  A major advantage to this last 
humanized mouse model is the development of a mucosal immune system and 
an extremely high level of engraftment. These BLT mice that show marked 
increases in hematopoietic engraftment and increased immune function are a 
good model to study human viral infections and in fact have been used to 
examine HIV, DENV, malaria, EBV, and Salmonella infections (Shultz et al., 
2007; Jaiswal et al., 2009; Libby et al., 2010; Shultz et al., 2010).  As a part of my 
thesis work I will be testing the resilience of these humanized mouse models 
upon infection with EBV and IAV to determine whether they are feasible to study 
human heterologous immunity. 
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Figure 1.6. History and family tree of the development of the humanized
mousemodels. Highlighted mice and arrows show the lineage of the modelsused in this study. The initial SCID mouse was crossed to the NODmouse tocreate NOD/SCID. NOD/SCID then crossed to IL2rγ-­‐/-­‐ to create the NSG mouse.NSG mice were then wascrossed to HLA-­‐A2 transgenic mice. Figure adapted byMike Brehm and Levi Watkin from Shultz et. al. Nature Reviews Immunology7:118-­‐130, 2007
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E. Thesis Objectives 
The gamma-herpes virus EBV infects ~95% of individuals globally, 
establishing a life-long infection (Henle et al., 1969). However, it is unknown why 
5-10% of adults remain EBV-SN, despite the fact that the virus infects the vast 
majority of the population and is actively shed at high titers even during chronic 
infection (Hadinoto et al., 2009).  Additionally, we have previously identified 
cross-reactive responses from IAV-GIL memory CD8 T-cells directed against two 
EBV epitopes EBV-GLC and EBV-YVL.  We hypothesize that heterologous 
immunity mediated by IAV-GIL specific memory CD8 T-cells cross-reactive 
against the EBV lytic epitopes EBV-GLC and EBV-YVL can protect EBV-SN 
adults from the establishment of productive EBV infection and sero-
conversion.  This thesis will be presented in two main parts: 
Chapter III: Demonstration and characterization of IAV-GIL memory CD8 T-cells 
cross-reactive to EBV lytic epitopes EBV-GLC and EBV-YVL in 
EBV-SN adults. 
a. What are the frequencies of the IAV-GIL cross-reactive 
population in the EBV-SN adults and how do they differ from 
EBV-SP adults? 
b. What are the effector functions that are responsible for 
mediating this protection? 
c. Are there any unique features of the TCR repertoire that could 
be mediating this protection? 
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Chapter IV: Characterization of viral infection in humanized mice for the 
establishment of a murine model to test protection from EBV 
infection mediated by heterologous immunity. 
a. Can these mice become infected with EBV and IAV? 
b. Can these mice mount an efficient immune response 
comparable to a human infection? 
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Chapter II: Materials and Methods 
Heterologous Immunity Within EBV-SN Adults 
EBV-SN Donors:  The 3 male and 2 female IAV-immune, EBV-SN 
patients ages 32-55 were consented volunteers.  Positive staining with 
HLA-A2-tetramers loaded with IAV-GIL was used as an indication that 
these individuals had been exposed to influenza A virus in the past.  For 
this study, a 50 mL blood sample was provided from patients.  All 5 
patients were seronegative for IgG antibodies to EBV EBNA and EBV viral 
capsid antigen.  EBV genomic DNA was not detected in peripheral blood 
using quantitative PCR performed as previously described (Hislop et al., 
2005).  The IRB committee at UMass Medical School approved this study. 
Blood preparation and bulk T-cell culture.  PBMC were isolated using 
Ficoll-paque plus (Amersham Bioscience, Uppsala, Sweden). CD8 cells 
were isolated using the Miltenyi Biotech (Auburn, CA) MACS system and 
were cultured using our published protocol (Clute et al., 2005).  Briefly, 
CD8 lymphocytes were plated at a 5:1 ratio with 1mM peptide-pulsed 
irradiated T2 cells (ATCC #CRL-1992), which were washed before 
combining with CD8 T-cells. They were used to re-stimulate the T-cell 
lines weekly.  Cell lines were given fresh media 3-4 days after stimulation. 
HLA-A2-restricted peptides and MHC-Class I tetramers and MHC-
Class I pentamers.  The following peptides were synthesized to >90% 
purity by Biosource (Camarillo, CA):  EBV-BMLF1280-288 (GLCTLVAML), 
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EBV-BRLF1109-117 (YVLDHLIVV), EBV-EBNA3A596-604 (SVRDRLARL), 
EBV-LMP2426-434 (CLGGLLTMV), IAV-M158-66 (GILGFVFTL), IBV-NP85-94 
(KLGEFYNQMM), measles virus M50-58 (FMYMSLLGV), and human 
endogenous tyrosinase369-377 (YMNGTMSQV).  A detailed description of 
the protocol used by the tetramer facility at UMass Medical School has 
been previously published (Catalina et al., 2001).  Tetramers, a tetrameric 
complex of pMHC molecules bound to streptiavidin, were assembled 
using the above peptide sequences and were conjugated to APC (Caltag, 
Burlingame, CA). MHC-Class I pentamers, a pentameric complex of 
pMHC molecules, were purchased from Proimmune (Oxford, UK).  Both 
tetramers and pentamers are reagents capable of detecting antigen 
specific CD8 T-cell populations. 
Extracellular/Intracellular staining and cell sorting.  Cells were plated 
at 106 per well and washed with FACS buffer (PBS, 2% FCS, 1% sodium 
azide).  Tetramers were incubated at room temperature for 20 min, 
followed by an additional 20 min incubation with monoclonal antibodies 
specific for CD3 (clone UCHT1 BD), CD4 (clone RPA-T4 BD), CD8 (clone 
HIT8a bio legend), or CD103 (clone Ber-ACT8 bio legend) according to 
the manufacturer’s protocols.  Samples were fixed in FixPerm (BD) and 
read on an LSRII (BD). 
 Cells stained for intracellular IFNγ and MIP1β were permeabilized with 
cytofix/cytoperm reagent (BD) and incubated 30 min at 4oC with anti-IFNγ 
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clone B27 (BD) and anti-MIP1β clone D211351.  Samples were read on a 
LSRII (Beckman Coulter, Fullerton, CA).  Cells for sorting were incubated 
with tetramer for 40 min at room temperature in 2% FCS/PBS buffer and 
were immediately isolated unfixed using the FACS Aria cell sorter 
(Beckman Coulter, Fullerton, CA). 
CDR3 clonotype analysis.  Clonotype analysis was performed as 
previously described (Cornberg et al., 2010a).  Briefly RNA was isolated 
from tetramer-sorted cells using the Qiagen Oligotex Direct mRNA mini kit 
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. cDNA 
was synthesized using the SMART RACE cDNA amplification kit from 
Clontech using the manufacturer’s protocol.  In place of the kit provided 
power-script for cDNA synthesis, Superscript III was used.  To amplify the 
TCR-β and -α specific genes the Advantage2 system was used according 
to the manufacturer’s protocol (Clonetech, Mountain View, CA).  For the 5’ 
forward primer the Universal Primer Mix from the SMART RACE cDNA 
amplification kit was used. To amplify the genes of interest a 3’ reverse 
primer specific to the TCR-β or -α region was used as reported previously 
(Brochet et al., 2008; Lefranc et al., 2009).  The PCR amplification 
program used was provided in the manufacturer’s protocol.  The resulting 
PCR product of appropriate size (~500-700 bp) was then gel purified using 
NucleoSpin Extract II kit according to the manufacturer’s protocol 
(Clonetech, Mountain View, CA).  Purified PCR product was then ligated 
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into the pCR4 vector from the TOPO TA cloning kit (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s protocol and transformed into DH5α 
E. coli from One Shot TOP10 chemically competent cells (Invitrogen, 
Carlsbad, CA), using the manufacturer’s procedures.  Colonies were then 
selected and amplified overnight for sequencing.   Amplified colonies were 
then preserved in 20% glycerol on dry ice and sent to Genewiz for 
sequencing.  Resulting sequences were then aligned using sequencher 
(Gene Codes Co. Ann Arbor, MI) and analyzed using IMGT/V-quest 
(Brochet et al., 2008; Lefranc et al., 2009). 
51Chromium release assay.  Autologous BLCLs created with either wild 
type EBV or a BZLF1 KO virus (Feederle et al., 2000) were used as target 
cells.  Cells were either untreated or treated with PMA at 10ng/ml 
overnight to induce the EBV lytic cycle.  Targets were labeled with 100mCi 
51Cr per 106 cells and the assay was performed as previously described 
(Brehm et al., 2002). Target cells were washed and plated at 2.5x104 
cells/ml.  Effector cells from CD8 T-cell lines were plated with targets at 8 
different effector-to-target ratios as indicated using 2-fold serial dilutions.  
Supernatants were then harvested and read on a MicroBeta TriLux 
scintillation counter (Perkin Elmer).  Lytic units were determined as 
previously described (F Pross and Maroun, 1984).  Briefly, lytic units are 
defined as the number of cells needed to kill x% of target cells.  For this 
study we used 15% killing of our target cells. Additionally, a portion of 
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untreated BZLF1 KO target cells were pulsed with 100mM of peptide for 1 
hour at 37 oC and the assay was conducted as stated above. 
Statistical Analysis:  Statistical analysis was performed using Prism 
version 5 (Graphpad Software Inc.).  Individual tests are indicated in figure 
legends.  Tests include Student’s T test and Simpson’s diversity index 
D=Σn(n-1)/N(N-1) where n is the number of individual clonotypes and N is 
the number of unique clonotypes (Venturi et al., 2007). 
Humanized Mice for the Study of Human Viral Infection 
Mice.  Three mouse models were used during this study.  The first 
model was of NOD.Cg-PrkdcSCIDIL2rgtmlWjl/Sz (NSG) mice that were 
developed at the Jackson Laboratory by crossing an IL2rg null 
mutation to the NOD.Cg-PrkdcSCID mouse (Shultz et al., 2005).  For the 
second model NOD.Cg-PrkdcSCIDIL2rgtmlWjlTg(HLA-A2/H2-D/B2M) 
1Dvs/Sz (NSG-HLA-A2/HHD) mice were made by backcrossing the 
(HLA-A/H2-D/B2M) transgene (Pascolo et al., 1997) from the 
NOD/ShiLtDvs-Tg(HLA/H2-D/B2M)1Dvs/J strain (Takaki et al., 2006) 
onto the NSG background (Shultz et al., 2010).  In the third model, BLT 
mice were generated by implanting 1mm3 pieces of human fetal liver 
and thymus under the kidney capsule of NSG-HLA-A2/HHD mice.  
Mice used from all three models were female. 
Purification of Human HSCs and Xenogeneic Transplantation.  For 
NSG mice HLA-A2+ cord blood samples were enriched for CD34+ 
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HSCs by using anti-hCD34 micro-beads (Miltenyi Biotech).  For NSG-
HLA-A2/HHD mice cord blood PBMCs were depleted of T-cells using 
anti-hCD3 micro-beads (Miltenyi Biotech) and CD34+ numbers were 
calculated from precursor frequencies.  Newborn (2-3 day old) mice 
were given total body irradiation of 150cGy followed by intra-cardiac 
injection of ~3x104 CD34+ HSCs.  Mice were allowed to reconstitute for 
12-20 weeks before infection. 
Virus Preparation and Infections.  The gastric carcinoma cell line 
AGS, harboring a GFP-expressing EBV, was induced to express virus 
as previously described (Borza and Hutt-Fletcher, 2002).  Briefly EBV-
harboring AGS cells were treated with 30ng per ml of 12-o-tetra-
decanoylphorbol-13-acetate and 2.5mM sodium butyrate overnight and 
allowed to secrete virus for 4 days. Supernatants were collected and 
filtered through 0.2mm filter and stored at -80oC.  Viral titrations were 
preformed as previously described (Strowig et al., 2009).  Briefly 1x104 
Raji cells were plated and infected with two-fold dilutions of virus stock.  
After two days Raji cells were examined for GFP expression by flow 
cytometry.  One unit was defined as the amount of virus needed to 
induce 50% maximal GFP expression.  IAV x31 was cultivated in 
embryonated chicken eggs (Szretter et al., 2006).  Mice were infected 
with 100 units of EBV intra-peritoneally (i.p.) and sacrificed 6-8 weeks 
after infection.  IAV infected mice were anesthetized with 
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methoxyflurane (Metafane™) and given 50 pfu in 50µL intra-nasally.  
Mice were then harvested 4 weeks after infection. 
Flow Cytometry Analysis.  Splenocytes were plated at a 
concentration of 1x106 cells/mL and washed and stained with 
monoclonal antibodies specific for hCD45 (clone HI30 BD), hCD3 
(clone UCHT1 BD), hCD4 (clone RPA-T4 BD), hCD8 (clone HIT8a bio 
legend), and HLA-DR (clone TU36 BD) according to the 
manufacturer’s protocols.  Samples were fixed in FixPerm (BD) and 
read on an LSRII (BD). 
Intracellular Cytokine Production.  Intracellular cytokine staining was 
performed as previously described (Shultz et al., 2010).  Briefly 
splenocytes were plated at a concentration of 1x106 cells/mL in RPMI-
1640 supplemented with 10% fetal calf serum (FCS), 10mg/mL 
brefeldin A, and 10 units/mL of IL-2.  Cells were either untreated or 
stimulated with 25ng phorbol 12-myristate 13-acetate and 10mg/mL of 
Ionomycin for 5 hours at 37oC and stained with monoclonal antibodies 
mentioned above and then permeabilized with Cytofix/Cytoperm (BD). 
Cells were then stained intracellularly with monoclonal antibodies 
specific to IFNγ (clone 4S.B3 ebiosciences) and granzyme B (clone 
16G6 E??ebiosciences).  Samples were read on an LSRII (BD). 
Histological Staining.  Hematoxylin/eosin (H&E) staining was 
performed on fixed sections of liver and lung tissue from EBV and IAV 
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infected animals, respectively.  Staining was performed using standard 
procedures. 
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Chapter III: Increased frequency of high avidity, lytic, cross-reactive CD8 T-
cells in EBV sero-negative adults 
The gamma-herpes virus Epstein-Barr virus (EBV) infects ~90% of 
individuals globally, establishing a life-long infection (Henle et al., 1969).  The 
clinical presentation of EBV infection can range from asymptomatic to severe, 
occasionally fatal, acute infectious mononucleosis  (AIM) (Crawford et al., 2006b; 
Luzuriaga and Sullivan, 2010).  There is also a strong causal relationship 
between EBV infection and malignancies, including carcinomas, and Burkitt’s 
lymphoma (Luzuriaga and Sullivan, 2010).  However, it is unknown why 5-10% of 
adults remain EBV-SN, despite the fact that the virus infects the vast majority of 
the population and is actively shed at high titers even during chronic infection 
(Hadinoto et al., 2009). Here, we show that EBV-SN HLA-A2+ adults possess 
cross-reactive IAV-GIL/EBV-GLC memory CD8 T-cells that show highly unique 
properties. These IAV-GIL cross-reactive cells preferentially expand, and 
produce cytokines to, EBV antigens with high functional avidity.  Additionally they 
are capable of lysing EBV-infected targets and show the potential to enter the 
mucosal epithelial tissue where infection is thought to initiate.  They also possess 
a TCR repertoire that differs by both organization and CDR3 usage from that in 
EBV-SP donors.  Our results imply that heterologous immunity may protect EBV-
SN adults against the establishment of productive EBV infection, and thus are 
the first demonstration of protective heterologous immunity between unrelated 
pathogens in sero-negative human subjects  
56
Here we question whether heterologous immunity mediated by cross-
reactive CD8 T-cells can protect EBV-SN adults from EBV infection and sero-
conversion. In murine studies, heterologous immunity facilitated by cross-reactive 
CD8 T-cell responses can mediate either beneficial (protective immunity) or 
detrimental effects (e.g., enhanced lung and adipose immunopathology) (Selin et 
al., 1998; Chen et al., 2001; Welsh and Selin, 2002; Welsh et al., 2010).  In this 
study we sought to determine if EBV-SN adults had an IAV-GIL/EBV-GLC cross-
reactive T-cell response with the potential to protect against the establishment of 
productive infection with EBV. 
A.  Characterization of EBV-SN adult donors 
For our study we procured blood samples from 5 HLA-A2+ healthy adult 
donors that were documented to be EBV sero-negative.  Three of the 5 donors 
were male and 2 were female.  The 5 donors ranged in age from 32-55 years of 
age.  One male and one female donor tested positive for CMV IgG.  Due to the 
possibility that these individuals could be EBV-SN yet still be infected with EBV, 
quantitative PCR for EBV DNA was performed on CD8 depleted PBMCs and 
found to be negative (table 1).   
To determine frequencies of IAV-GIL, EBV-GLC, and EBV-YVL reactive 
CD8 T-cells ex vivo, tetramer staining was performed on sorted CD8 T-cells from 
peripheral blood mononuclear cells (PBMCs).  IAV-GIL frequencies ranged from 
0.07-1.2% of the CD8 T-cell pool, with a mean of 0.41+/-0.42% and an MFI of 
1164+/- 23 while EBV-GLC and EBV-YVL tetramer staining, if present, was very 
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dim (Fig 3.1).  Dim EBV-GLC tetramer staining frequencies ranged from 0-0.27% 
of the CD8 T-cell pool, with a mean of 0.13+/-0.11% and an MFI of 180+/- 135.  
Dim EBV-YVL tetramer staining frequencies ranged from 0-0.08%s of the CD8 T-
cell pool, with a mean of 0.05+/-0.03% with an MFI of 384+/-542 (table 1).  
Control tyrosinase tetramer staining exhibited no staining (Fig 3.1). 
B.  Increased frequencies of IAV-GIL tetramer positive cells detected in 
EBV-SN adults 
Immunological memory is the mechanism by which an individual is protected 
from secondary infection.  In heterologous immunity immunological memory 
developed in response to one pathogen has an impact on the response to a 
secondary unrelated pathogen.  Previously we have reported that IAV-GIL 
memory CD8 T-cells have the ability to recognize EBV-GLC and participate in 
mediating AIM (Clute et al., 2005).  Here we wanted to determine the frequency 
of IAV-GIL reactive cells in EBV-SN adults directly ex vivo.  To determine the 
frequencies of IAV-GIL reactive CD8 T-cells, tetramer staining was performed on 
sorted CD8 T-cells from donor PBMCs.  Within the EBV-SN adults there was a 
significant 7-fold higher frequency of IAV-GIL tetramer+ cells detected directly ex 
vivo as compared to EBV-SP donors (EBV-SN: 0.42 +/-0.4 vs. EBV-SP: 0.06 +/-
0.03: p=0.003) (Fig 3.1). 
This increase in frequency of IAV-GIL reactive cells, some of which have 
been previously shown to be cross-reactive to EBV-GLC, suggests that the EBV-
58
 
Donors D01 D02 D03 D04 D05 
Age 37 43 32 55 55 
Sex M M M F F 
EBV EBNA IgG - - - - - 
EBV VCA IgM - - - - - 
EBV VCA IgG - - - - - 
EBV Genome 
PCR - - NP NP NP 
CMV IgG - - + - + 
IAV-GIL 0.5 0.07 1.19 0.14 0.17 
EBV-GLC 0.03 0 0.21 0.27 0.13 
EBV-YVL 0 0.05 0.04 0.08 0.08 
Table 3.1:  EBV-SN donor characterization.  EBV-SN donor 
sex, age, sero-status, and indicated tetramer frequencies within 
the CD8 T-cell pool determined ex vivo.  EBV genome PCR 
performed on both peripheral blood and throat wash.  NP Not 
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SN donors may have a heightened sensitivity to the early EBV antigen EBV-
GLC. 
C.  IAV-GIL tetramer positive cells preferentially expand when cultured in 
the presence of EBV antigens 
Now that we had observed that there is an increase in the precursor 
frequency of the potentially cross-reactive IAV-GIL restricted CD8 T-cells, we 
next wanted to start investigating their effector functions.  Even though there was 
a relatively high frequency of IAV-GIL restricted cells within EBV-SN donors, the 
corresponding number of cells that can be recovered ex vivo is too small to be 
able to conduct functional experiments.  In order to procure enough cells we 
used an in vitro system. 
Sorted CD8 T-cells were plated at a concentration of 2.5x105 cells per ml 
with irradiated T2 feeder cells at a concentration of 5x104 cells per ml.  Feeder 
cells were coated with 1µM of indicated HLA-A2 restricted peptides.   Media were 
replaced every 3-4 days and cells were re-stimulated every 7 days.  After 3 
stimulations cells had expanded enough to use in functional assays.   
Interestingly, when sorted CD8 cells from EBV-SN adults were cultured in 
the presence of EBV lytic peptides, EBV-GLC or –YVL, the same frequency of 
IAV-GIL tetramer+ cells expanded as compared to CD8 cells cultured in the 
presence of IAV-GIL.  Importantly, feeder cells only, an irrelevant control 
tyrosinase peptide, or an unrelated viral epitope CMV-pp65 (CMV-NLV), did not 
induce expansion of IAV-GIL specific cells (Fig 3.2).  Cross-reactive IAV-GIL
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 tetramer+ cells growing in EBV-GLC or -YVL peptide-stimulated cell lines of 
EBV-SP donors are frequently observed (Clute et al., 2005; 2010; Cornberg et 
al., 2010a) (Fig 3.2a,b).  However, the IAV-GIL-specific cells from EBV-SN 
adults expanded 7- and 4-fold greater than in EBV-GLC or -YVL peptide-
stimulated cell lines from EBV-SP donors, respectively (Fig 3.2c).  Notably, IAV-
GIL specific cells had a statistically significant higher fold expansion within EBV-
SP donors than EBV-SN donors when cultured in the presence of IAV-GIL.  This 
is an artifact of the calculation due to the significantly lower starting frequency of 
IAV-GIL reactive cells present ex vivo as compared to EBV-SN donors (Fig 
3.2c). 
D.  IAV-GIL memory cells are necessary for EBV antigen mediated 
expansion  
To show that this cross-reactive EBV induced expansion of IAV-GIL 
restricted CD8 T-cells is a special feature of EBV-SN adult donors, and not an 
inherent reactivity of all IAV-GIL CD8 T-cells, CD8 T-cells from immunologically 
naïve HLA-A2+ cord-blood PBMCs were examined.  CD8 T-cells were subjected 
to the same in vitro procedure as described above. 
Antigen experienced IAV-GIL-specific CD8 T-cells appeared to be 
required for EBV-GLC or -YVL induced expansion, as expansion did not arise 
from immunologically naïve (never exposed to IAV or EBV) HLA-A2+ cord-blood 
CD8 T-cells (Fig 3.3).  As previously reported, there was a small expansion of 
IAV-GIL reactive cells from the cord blood but only in cell lines grown in the 
63
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presence of IAV-GIL peptide and only in response to IAV-GIL peptide and not to 
EBV-GLC or –YVL (Lawson et al., 2001).  These results imply that this strong 
proliferation in response to EBV-GLC or -YVL peptide is not an inherent property 
of all IAV-GIL reactive T-cells, but is unique to the IAV-GIL memory population in 
these EBV-SN adults. 
E.  IAV-GIL tetramer positive cells are functionally cross-reactive as 
demonstrated by cytokine production 
An additional ability of CD8 T-cell effector function is the ability to secrete 
antiviral cytokines. To further elucidate the cross-reactive effector function of the 
IAV-GIL restricted CD8 T-cells expanded by EBV lytic epitopes from EBV-SN 
adult donors, an intracellular cytokine-staining (ICS) assay was performed. 
The majority of the IAV-GIL tetramer+ cells in the IAV-GIL, EBV-GLC and 
-YVL stimulated CD8 lines from EBV-SN adults produced IFNγ  and MIP1β in 
response to IAV-GIL in (ICS) assays (Fig 3.4a,b). Remarkably, as seen with 
donor 1 (Fig 3.4a), 37% of the IAV-GIL tetramer+ cells from the IAV-GIL peptide-
stimulated line produced IFNγ in response to EBV-GLC stimulation.  In the EBV-
GLC and -YVL peptide-stimulated lines an even greater proportion, 83-88% of 
the IAV-GIL tetramer+ cells produced IFNγ in response to EBV-GLC stimulation 
(Fig 3.4a).  EBV-YVL peptide-stimulated IAV-GIL tetramer+ cells produced IFNγ, 
in the IAV-GIL, EBV-GLC and -YVL peptide-stimulated lines, however it was a 
lower proportion of cells (Fig 3.4a).  This cross-reactivity was specific and 
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restricted to these 3 epitopes, as peptide stimulation with other viral and self-
epitopes did not induce cytokine production (Fig 3.4a,b). 
These data demonstrate that IAV-GIL-specific cells from EBV-SN adults 
expanded by cognate (IAV-GIL) or cross-reactive (EBV-GLC, or –YVL) peptides 
could produce antiviral cytokines in response to EBV epitopes and were 
functionally cross-reactive. These results also suggest that the IAV-GIL-specific 
TCR repertoires in the 3 cultures may differ, as different proportions of the 
population were able to produce IFNγ to the cross-reactive ligands, EBV-GLC 
and -YVL.  
F.  IAV-GIL restricted cells have high avidity to IAV-GIL and EBV-GLC 
An additional characteristic of memory CD8 T-cells is an enrichment of 
high functional avidity cells.  CD8 T-cells with higher avidity usually result in 
increased effector function (Alexander-Miller, 2005).  
To decipher the functional avidity of these cross-reactive responses, these 
cell lines were stimulated with 10-fold serial dilutions of IAV-GIL or EBV-GLC 
peptides, and IFNγ production was measured. An effective concentration that 
resulted in 50% maximal IFNγ production (EC50) was then calculated.  
Unexpectedly, the cognate IAV-GIL functional avidity as measured by EC50 in 
the IAV-GIL lines from the EBV-SN adults was 10-fold higher (10-8.5 ± 0.4M, n=3) 
than in the EBV-SP adult lines (10-7.3 ± 0.3M, n=4) (p=0.05) (Fig 3.5a).  The EBV-
GLC functional avidity as measured by EC50 in the EBV-GLC lines from the 
EBV-SN adults was nearly 100-fold higher (10-8.6±0.3M, n=3) as compared to the 
67
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EBV-SP adult lines (10-7.0±0.5M, n=4)(p=0.05) (fig 3.5a). It is surprising that CD8 
T-cells with this high functional avidity did not bind EBV-GLC or EBV-YVL 
tetramer (Fig 3.5b).  However, similar findings have been shown in which antigen 
specific cells from in vitro generated cell lines are capable of producing cytokines 
in response to peptide ligands, but are unable to bind tetramers (Spencer and 
Braciale, 2000; Sabatino et al., 2011).  There may be a possibility that the EBV-
GLC and –YVL peptides are being presented by an alternate MHC.  While 
unlikely due to their HLA-A2 restriction this could be tested for by blocking EBV-
GLC pMHC-TCR interactions with a HLA-A2 blocking antibody.  If the responses 
remained then that would indicate that there may be another mechanism 
involved.  This result would not rule out heterologous immunity and cross-
reactive memory CD8 T-cells as the mechanism mediating these events, as it is 
primarily the IAV-GIL tetramer positive cells that produce cytokine in response to 
EBV-GLC and –YVL peptides (Fig 3.4). 
These data show that EBV-SN adults have EBV-GLC reactive cells with 
significantly higher functional avidity to EBV-GLC than do EBV-SP individuals, 
perhaps selected for by low dose exposure to antigen.  These data suggest that 
these EBV-GLC reactive cells may be able to protect against the establishment 
of productive EBV infection. 
G.  Cross-reactive CD8 T-cells in EBV-SN adults lyse EBV-infected and 
peptide-coated autologous BLCL targets 
69
The most important hallmark of CD8 T-cell function is the ability to kill 
tumor cells and virus infected cells.  To do this a CD8 T-cell must see its antigen 
in the context of a peptide-MHC (pMHC) complex.  CD8 T-cells must be 
educated to recognize the MHC of the individual during thymic development.  
CD8 T-cells that pass thymic selection then migrate to the periphery and join the 
naïve T-cell pool.  If a CD8 T-cell interacts with a MHC other than the ones on 
which it has been selected on the cells can exert their effector function in 
response to an alloantigen.  
In order to test whether these cross-reactive IAV-GIL-specific cells from 
these EBV-SN adults could kill EBV-infected targets, and to avoid any allo-
reaction, autologous B lympho-blastoid cell lines (BLCLs) were generated from 
two of the donors. The fact that we were able to generate BLCL is evidence that 
B-cells from EBV-SN individuals can be infected with EBV.  As a control, 
infecting autologous B cells with BZLF1 KO EBV created autologous BLCLs 
incapable of presenting lytic antigens.  BZLF1 is required for reactivation from 
latent to lytic cycle and leads to the expression of the lytic proteins BMLF1 and 
BRLF1 (Feederle et al., 2000).  By using these target cells and also HLA-A2-
restricted peptide-coated autologous BZLF1-KO BLCL targets we demonstrate 
that these cross-reactive CD8 T-cells are capable of killing EBV-infected targets 
in a lytic antigen-dependent manner. CD8 T cell lines grown in the presence of 
IAV-GIL, EBV-GLC, or -YVL peptides were able to lyse WT autologous BLCL 
targets but not the BZLF1 KO autologous BLCL targets (Fig 3.6a-b).  These CD8
70
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 lines also lysed IAV-GIL, EBV-GLC, or -YVL peptide-loaded targets but not 
control targets (Fig 3.6c).  This ability of EBV-SN adult CTL to kill EBV-infected 
and EBV-peptide-loaded targets suggests that these IAV-GIL cross-reactive cells 
have the potential to protect against EBV infection. 
H.  IAV-GIL tetramer positive cells show potential to enter the mucosal 
epithelium 
Recent findings have suggested that effector cells in the initial site of 
infection can mediate protection from the establishment of infection, particularly 
in the mucosa (Hansen et al., 2011).  While it was long thought that EBV only 
infects memory B-cells, recent findings have shown that EBV can also infect 
epithelial cells of the tonsillar mucosa (Arvin et al., 2007).  Here we wished to 
determine whether this unique population of IAV-GIL specific cells from EBV-SN 
adults have the ability to enter the mucosal epithelium.  
To determine whether these EBV-specific cross-reactive cells could 
migrate into the site of initial viral replication, such as the linguinal and tonsillar 
mucosal epithelial tissues, tetramer+ cells were stained directly ex vivo for the 
expression of CD103, an integrin molecule associated with migration into these 
tissues (Schön et al., 1999). There was a significant 4-fold higher frequency of 
CD103 expressing (6.3±1.3%, n=3) IAV-GIL tetramer+ cells in EBV-SN adults as 
compared to EBV-SP adults (1.5±1.0%, n=5) (Fig 3.7). Also, there was a 
significant 40-fold higher frequency of CD103-expressing dim EBV-GLC 
tetramer+ cells directly ex vivo in the EBV-SN adults at 10.1±2.2% (n=3), as
72
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 compared to only 0.25±0.21% (n=5) of the bright EBV-GLC tetramer+ cells in 
EBV-SP adults (Fig 3.7).  These data suggest that the IAV-GIL and the dim EBV-
GLC tetramer+ cells from EBV-SN adults have the appropriate antigen display to 
enter mucosal epithelial tissues.  Antigen exposure is required for CD103 
expression of CD8 T-cells (Lee et al., 2011).  This would suggest that these EBV-
GLC reactive cells that express CD103 could be seeing continuous low level 
antigen exposure. 
I.  IAV-GIL restricted CD8 T-cells within EBV-SN adult use a different TCR β 
chain 
Due to the unique features of the IAV-GIL restricted CD8 T-cells within 
EBV-SN adult donors we next questioned whether there were any unique 
features in the IAV-GIL-specific TCR repertoire that could explain why these 
EBV-SN adults might have protective immunity.  Figure 3.8a shows a 
representative example of the well characterized IAV-GIL-specific TCR repertoire 
in a middle-aged EBV-SP donor (Lehner et al., 1995; Lawson et al., 2001; 
Naumov et al., 2008; Clute et al., 2010).  This and other EBV-SP donors typically 
have a polyclonal response restricted by a public Vβ19 usage, primarily 
expressing xRSx complementarity determining region 3 (CDR3) motif (~90% of 
clonotypes), that predominantly utilizes Jβ2.7 (Naumov et al., 2006).  Within 
EBV-SN donors, Vβ usage by IAV-GIL tetramer+ cells in the lines grown in the 
presence of IAV-GIL, EBV-GLC or -YVL antigen primarily used Vβ19, as 
demonstrated by antibody staining (data not shown) and CDR3β sequencing (Fig
74
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 3.8, Table 3.2).  The dominant clonotype in donor 1, rather than containing the 
common xRSx motif used by EBV-SP donors, contained a non-canonical IVGG 
motif and used an uncommon Jβ2.1 instead of the common Jβ2.7 used by EBV-
SP adults (Fig 3.8).  Unique Vβ19 TCR repertoires were observed in the other 
EBV-SN donors (Table 3.2). 
J.  EBV-SN donors have a different IAV-GIL specific TCR repertoire 
organization 
In contrast to EBV-SP donors, the CDR3β repertoire within the IAV-GIL-
restricted response from the IAV-GIL, EBV-GLC and -YVL lines from the EBV-SN 
adults was less diverse and oligo-clonal.  To quantitate the diversity of the TCR 
repertoire Simpson’s diversity index was used (Venturi et al., 2007).  The Vβ19 
CDR3β repertoire of the IAV-GIL response was significantly less diverse within 
EBV-SN adults as compared to EBV-SP adults (Fig 3.9).  
K.  IAV-GIL restricted CD8 T-cells within EBV-SN adult use different Vα 
chain 
The Vα repertoire organization in the IAV-GIL restricted T-cell population 
of EBV-SP donors was similar to that of the Vβ repertoire, in that it was highly 
diverse with no dominating clonotypes (Clute et al., 2010).  The Vα repertoire 
predominantly used Vα27, with some additional usage of Vα10, 8.6, and 34, 
most often combined with Jα42.  However, like the Vβ repertoire organization, in 
all 3 representative EBV-SN adults, the Vα repertoire was not polyclonal but 
instead was dominated by one or two clonotypes (Fig 3.10).   Interestingly, the 
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VB family JB family CDR3 amino acid sequence # of copies VB family JB family CDR3 amino acid sequence # of copies VB family JB family CDR3 amino acid sequence # of copies
BV19 BJ2.5 CASSSRSGWTQYFGPG 50 BV19 BJ2.2 CASSSRSTGELFFGEGS 23 BV19 BJ2.7 CASSIRSAYEQYFGPGT 13
BV19 BJ2.7 CASSIRSSYEQYFGPG 11 BV19 BJ2.7 CASSVRSSYEQYFGPGT 14 BV19 BJ1.5 CASSIFSNQPQHFGDGT 10
BV19 BJ2.7 CASSIRSSYEQYFGPG 11 BV19 BJ2.7 CASSSRSAYEQYFGPGT 13 BV19 BJ1.2 CASSIGHYGYTFGSGT 10
BV19 BJ1.5 CASSYYSNQPQHFGDG 7 BV19 BJ1.5 CASSIPTVSVGAQHFGDGT 12 BV19 BJ1.1 CASSIRSVAEAFFGQGT 9
BV19 BJ2.7 CASSIRSAYEQYFGPG 3 BV19 BJ2.7 CASSTRSGYEQYFGPGT 9 BV19 BJ1.1 CASSIRSGNTEAFFGQGT 7
BV19 BJ2.7 CASSIRSAYEQYFGPG 3 BV19 BJ2.1 CASSIRSTHEQFFGPGT 6 BV19 BJ2.3 CASSIVHAADTQYFGPGT 6
BV19 BJ2.7 CASSIEQYYEQYFGPG 3 BV19 BJ2.2 CASSIRSTGELFFGEGS 4 BV19 BJ1.1 CASSIRSVAEAFFGQGT 6
BV19 BJ2.3 CASSTRSTDTQYFGPG 3 BV19 BJ2.1 CASSSRSGHEQFFGPGT 4 BV19 BJ1.5 CASSTLTGGHQPQHFGDGT 5
BV19 BJ2.7 CASSIRSSYEQYFGPG 2 BV19 BJ1.5 CASSFYSNQPQHFGDGT 3 BV19 BJ2.3 CASSVRSGDTQYFGPGT 4
BV19 BJ2.7 CASSIRSSYEQYFGPG 2 BV19 BJ2.7 CASSIRSAYEQYFGPGT 2 BV19 BJ2.7 CASSIRSSYEQYFGPGT 3
BV19 BJ2.3 CASSSRSTDTQYFGPG 2 BV19 BJ2.7 CASSTRSSYEQYFGPGT 2 BV19 BJ1.2 CASSQGFYGYTFGSGT 3
BV19 BJ2.3 CASETTSTDTQYFGPG 2 BV19 BJ2.7 CASSIRSAYEQYFGPGT 2 BV19 BJ2.7 CASSIRSAYEQYFGPGT 2
BV19 BJ1.4 CASSIRSTEKLFFGSG 2 BV19 BJ1.1 CASSIRAATEAFFGQGT 2 BV19 BJ2.1 CASSIFSAGNEQFFGPGT 2
BV19 BJ1.1 CASSIRSDAEAFFGQG 2 BV19 BJ2.7 CASSIRSAYEQYFGPGT 1 BV19 BJ2.1 CASSILGASYNEQFFGPGT 2
BV19 BJ1.1 CASTHSAISEAFFGQG 2 BV19 BJ2.7 CASSIRAGVEQYFGPGT 1 BV19 BJ1.5 CASSIRSGEPQHFGDGT 2
BV19 BJ2.7 CASSIRSSYEQYFGPG 1 BV19 BJ2.7 CASSVQEGPTYEQYFGPGT 1 BV19 BJ1.2 CASSMGSYGYTFGSGT 2
BV19 BJ2.7 CASSIRSSYEQYFGPG 1 BV19 BJ2.7 CASSLRASGEQYFGPGT 1 BV19 BJ1.1 CASSIHSGGNTEAFFGQGT 2
BV19 BJ2.7 CASSIRSAYEQYFGPG 1 BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.7 CASSIRSSYEQYFGPGT 1
BV19 BJ2.7 CASSIRSAYEQYFGPG 1 BV19 BJ2.7 CASSIRSAYEQYFGPGT 1 BV19 BJ2.7 CASSIRSSYEQYFGPGT 1
BV19 BJ2.7 CASSILASYEQYFGPG 1 BV19 BJ2.7 CASSPASGSYEQYFGPGT 1 BV19 BJ2.7 CASSIRSSYEQYFGPGT 1
BV19 BJ2.7 CASSTLASYEQYFGPG 1 BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.7 CASSIRSAYEQYFGPGT 1
BV19 BJ2.7 CASSTGTSWEQYFGPG 1 BV19 BJ2.3 CASSIRSTDTQYFGPGT 1 BV19 BJ2.7 CASSIRSSYEQYFGPGT 1
BV19 BJ2.5 CASSSCSGWTQYFGPG 1 BV19 BJ2.3 CASSIRSTDTQYFGPGT 1 BV19 BJ2.7 CASSTRSAYEQYFGPGT 1
BV19 BJ2.3 CASSIRSTDTQYFGPG 1 BV19 BJ2.3 CASSTRSADTQYFGPGT 1 BV19 BJ2.7 CASSARVGNEQYFGPGT 1
BV19 BJ2.3 CASSIFQTDTQYFGPG 1 BV19 BJ2.3 CASSTIAGGTDTQYFGPGT 1 BV19 BJ2.7 CASSMRSAYEQYFGPGT 1
BV19 BJ2.2 CASSITHTGELFFGEG 1 BV19 BJ2.2 CASSSRSAGELFFGEGS 1 BV19 BJ2.5 CASSTRSQETQYFGPGT 1
BV19 BJ2.1 CASSIRSGFEQFFGSG 1 BV19 BJ2.2 CASSRRSTGELFFGEGS 1 BV19 BJ2.5 CASSARSAETQYFGPGT 1
BV19 BJ2.1 CASSIDGGNEQFFGPG 1 BV19 BJ2.1 CASSIFGLNEQFFGPGT 1 BV19 BJ2.3 CASSIRSTDTQYFGPGT 1
BV19 BJ1.2 CASSNQGPVGYTFGSG 1 BV19 BJ2.1 CASSISAGPYNEQFFGPGT 1 BV19 BJ2.3 CASSALGAGGDTQYFGPGT 1
BV19 BJ1.1 CASSIGSATEAFFGQG 1 BV19 BJ2.1 CASSILGLHEQFFGPGT 1 BV19 BJ2.3 CASSMRSTDTQYFGPGT 1
Clonotypes :30 BV19 BJ2.1 CASSMGLVSFGQFFGPGT 1 BV19 BJ2.2 CASSTRAAGELFFGEGS 1
Sequences:120 120 BV19 BJ2.1 CASSIRSSYNEQFFGPGT 1 BV19 BJ2.1 CASSIRSSYNEQFFGPGT 1
BV19 BJ2.1 CASSIKSSYNEQFFGPGT 1 BV19 BJ2.1 CASSASGRYNEQFFGPGT 1
BV19 BJ1.6 CASSIGNSPLHFGNGT 1 BV19 BJ1.5 CASSVYSNQPQHFGDGT 1
VB family JB family CDR3 amino acid sequence # of copies BV19 BJ1.6 CASSASRGEVGSPLHFGNGT 1 BV19 BJ1.2 CASSIGLYGYTFGSGT 1
BV19 BJ2.7 CASSIRSSYEQYFGPGT 10 BV19 BJ1.5 CASSVGLGQPQHFGDGT 1 Clonotypes :35
BV19 BJ2.1 CASSGRAGVEQFFGPGT 8 BV19 BJ1.5 CASSIPTVSVGAQHFGDGT 1 Sequences :106 106
BV19 BJ2.1 CASSIGTGEQFFGPGT 7 BV19 BJ1.5 CASSPRSSEPQHFGDGT 1
BV19 BJ2.7 CASSIRAAYEQYFGPGT 5 BV19 BJ1.5 CASSPGQDYQPQHFGDGT 1
BV19 BJ2.3 CASSPRSGDTQYFGPGT 5 BV19 BJ1.3 CASSTPDRGTISGNTIYFGEGS 1
BV19 BJ2.7 CASSIRSSYEQYFGPGT 4 BV19 BJ1.2 CASSPPFVGGHGYTFGSGT 1
BV19 BJ2.7 CASSIRSSYEQYFGPGT 4 BV19 BJ1.1 CASSIPATEAFFGQGT 1
BV19 BJ2.7 CASSPRSSYEQYFGPGT 4 Clonotyes:42
BV19 BJ2.7 CASSIRSSYEQYFGPGT 3 Sequences:125 !"#
BV19 BJ2.7 CASSMRSSYEQYFGPGT 3
BV19 BJ2.2 CASSISSTGELFFGPGT 3
BV19 BJ2.7 CASSIRSSYEQYFGPGT 2 VB family JB family CDR3 amino acid sequence # of copies
BV19 BJ2.7 CASSIRSSYEQYFGPGT 2 BV19 BJ2.1 CASSIRAGYEQFFGPGT 40
BV19 BJ2.7 CASSIRSSYEQYFGPGT 2 BV19 BJ1.5 CASSIRSNQPQHFGDGT 16
BV19 BJ2.7 CASSIRSSYEQYFGPGT 2 BV19 BJ2.7 CASSIRSSYEQYFGPGT 6
BV19 BJ2.7 CASSTRSSYEQYFGPGT 2 BV19 BJ1.5 CASSRRSTQPQHFGDGT 6
BV19 BJ2.7 CASSSRSSYEQYFGPGT 2 BV19 BJ2.3 CASSTSSTDTQYFGPGT 5
BV19 BJ2.5 CASSSRSGETQYFGPGT 2 BV19 BJ2.2 CASSLRSTGELFFGEGS 5
BV19 BJ2.1 CASSGQAGVEQFFGPGT 2 BV19 BJ2.2 CASSQRSTGELFFGEGS 3
BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ1.3 CASSMRSGNTIYFGEGS 3
BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.7 CASSIRSGYEQYFGPGT 2
BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.7 CASSMRSSYEQYFGPGT 2
BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.3 CASSIRSTDTQYFGPGT 2
BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.2 CASSITGGEGGELFFGEGS 2
BV19 BJ2.7 CASSIRSSYEQYFGPGT 1 BV19 BJ2.7 CASSTRSTYEQYFGPGT 1
BV19 BJ2.7 CASSTRSSYEQYFGPGT 1 BV19 BJ2.7 CASSIYRLGYEQYFGPGT 1
BV19 BJ2.7 CASSLRSSYEQYFGPGT 1 BV19 BJ2.3 CASSTWSTDTQYFGPGT 1
BV19 BJ2.7 CASSIRTSYEQYFGPGT 1 BV19 BJ2.2 CASSGRSAGELFFGEGS 1
BV19 BJ2.7 CASSSRSAYEQYFGPGT 1 BV19 BJ2.2 CASSLRSTGELFFGEGS 1
BV19 BJ2.7 CASSSRASYEQYFGPGT 1 BV19 BJ1.5 CASSRRSTQPQHFGDGT 1
BV19 BJ2.5 CASSSRSGETQYFGPGT 1 Clonotypes :18
BV19 BJ2.3 CASSSRSTDTQYFGPGT 1 Sequences :98 $%
BV19 BJ2.3 CASSPRSGDTQYFGPGT 1
BV19 BJ2.3 CASSGRGTDTQYFGPGT 1
BV19 BJ2.3 CASSTRSTDTQYFGPGT 1
BV19 BJ2.3 CASSPRSGDTQYFGPGT 1
BV19 BJ2.1 CASSIRSSVEQFFGPGT 1
BV19 BJ2.1 CASSIRSGGEQFFGPGT 1
BV19 BJ1.2 CASSIGIYGYTFGPGT 1
BV19 BJ1.1 CASSIRDGVNTEAFFGPGT 1
Clonotypes :40
Sequences :93 !"
EBV-SP IAV-GIL Line VB Usage
Donor 4 (Codja D 012)
Donor 6 (Selli D 002)
Donor 3 (Fliam)
Donor 2 (Gilko)
Donor 1 (Gilan)
Table 3.2. Clonal composition of the IAV-­‐GIL TCR beta repertoire within
EBV-­‐SP adults. 5 EBV-­‐SP donors showing the distribution of IAV-­‐GIL reactiveclones showing V-­‐β family and J-­‐β family usage, CDR3 amino acid compositions,and number of clones detected.
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Figure 3.9: Significantly decreased diversity of the IAV-GIL specific V  
TCR repertoire in EBV-SN as compared to EBV-SP donors as 
demonstrated by using the Simpson Diversity Index.  For these studies 
IAV-GIL tetramer+ cells were sorted from each cell line, and subjected to 
SMART-Race PCR to identify individual clonotypes by sequencing the CDR3  
as shown in tables 3.2 and 3.3. 
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dominant clonotypes contained either Vα27 or Jα42, but not both together as 
was usually observed in the EBV-SP.   Donor 1 T-cells used predominantly 
Vα27Jα10, whereas the other two donors used Jα42 but not Vα27 (Table 3.3). 
L.  Repertoire organization coincides with differential cytokine production 
When we compared both the Vα and β TCR repertoires of the IAV-GIL-
specific cells between the 3 different epitope stimulated lines from donor 1 it was 
evident that the most dominant clonotype was identical in each line (Fig 3.8, & 
3.10). However, the EBV-YVL line did have a second dominant Vα clonotype that 
was present only at low frequency in the other two cultures. The sub-dominant 
IAV-GIL-specific Vα and β clonotypes differed significantly between the cultures, 
suggesting that each epitope could select a different group of T-cell clones. 
These differences in TCR repertoire would be consistent with the different 
patterns of functional cytokine responses in each culture upon stimulation with 
the 3 different cross-reactive ligands (Fig 3.4).  
M.  Summary 
I have therefore demonstrated that the IAV-GIL-restricted memory pool in 
EBV-SN adults possessed a highly functional cross-reactive response that 
reacted against EBV lytic antigens.  These cross-reactive T-cell responses were 
shown by their ability to proliferate and secrete protective antiviral cytokines such 
as IFNγ and MIP-1β in response to EBV lytic antigens. Additionally, CD8 T-cells 
from these EBV-SN adults were able to kill EBV-infected targets in a lytic antigen 
dependent manner, and they also killed EBV lytic antigen peptide-loaded targets.
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VB family JB family CDR3 amino acid sequence # of copies VA family JA family
CDR3 amino acid 
sequence # of copies
!"#$ !%&'# CASSIVGGNEQFF ($ )"&* )%#+ CADVRGTGGGNKLTF ,*
!"#$ !%&'* CASSIRSSYEQYF , )"&- )%(& CAANYGGSQGNLIF #,
!"#$ !%&'* CASSIRSAYEQYF # )"&* )%,* CAGDGSSNTGKLIF *
!"#$ !%&'* CASSFDGVYEQYF # )"#+ )%,# CVVSANNNARLMF *
!"#$ !%&', CASSARATDTQYF # )"#&'( )%,* CAVRLSNTGKLIF (
!"#$ !%&', CASSGRSADTQYF # )"#( )%#+ CAMREPRRGGGGNKLTF &
!"#$ !%&'& CASSMRSTRELFF # )"#, )%$ CAASTPPGTGGFKTIF &
!"#$ !%&'# CASSIIGGYEQFF # )"#* )%,# CATCRNNNARLMF &
!"#$ !%&'# CASSIVGGNEQFF # )"&* )%(& CAGEGGGSQGNLIF #
!"#$ !%&'# CAGSIVGGNEQFF # )"&* )%(& CAAGGSQGNLIF #
!"#$ !%&'# CASSIVGGNGQFF # )"&* )%,* CAGASGSSNTGKLIF #
!"#$ !%#'# CASSSHAGGNTEAFF # )"&* )%,* CAGAPGSSNTGKLIF #
!"#. !%&'* CASSLTGSTYEQYF # )"#&'# )%-& CVPPEAGGTSYGKLTF #
Clonotyes:13 Clonotyes:13
Sequences:63 !" Sequences:79 #$
VB family JB family CDR3 amino acid sequence # of copies VA family JA family
CDR3 amino acid 
sequence # of copies
!"#$ !%#'( CASSIFGEKLFF 32 )"&/'& )%(& CILRDLTLGGSQGNLIF ,$
!"#$ !%&'* CASSIRSAYEQYF 12 )"&* )%(& CAGGGSQGNLIF .
!"*'& !%&'* CASSLVGTGPYEQYF 2 )"&- )%(& CAGNYGGSQGNLIF -
Clonotyes:3 )",/ )%(, CAVDPSYNNNDMRF (
Sequences:46 %! )"&* )%,* CAGARGSSNTGKLIF ,
)"#,'& )%(& CAENGGGGSQGNLIF ,
)",.'& )%&, CAYRGLFYNQGGKLIF &
)"#,'& )%(& CAASGGGSQGNLIF &
)"#&', )%(& CAMSGDGGSQGNLIF #
Clonotyes:9
Sequences:67 !#
VB family JB family CDR3 amino acid sequence # of copies VA family JA family
CDR3 amino acid 
sequence # of copies
!"#$ !%&'# CASSIVGGNEQFF -# )"&* )%#+ CADVRGTGGGNKLTF ,-
!"#$ !%&'* CASSIRSSYEQYF - )"#&'( )%,* CAVRLSNTGKLIF /
!"#$ !%#'# CASSSHAGGNTEAFF ( )"- )%#. CAETTTDRGSTLGRLYF /
!"#$ !%#'- CASSWLSNQPQHF ( )"&- )%(& CAANYGGSQGNLIF ,
!"#$ !%&'# CAGSIVGGNEQFF ( )",.'& )%-& CAYAANAGGTSYGKLTF ,
!"#$ !%&'& CASSMRSTGELFF ( )"#,'& )%(& CAENIGGGSQGNLIF &
!"#$ !%&'# CASSTYSTNEQFF # )"&- )%(& CAANYGGSQGNLIF &
!"#$ !%&'& CASSLRSSGELFF # )",- )%(+ CAGQPGTYKYIF &
!"#$ !%&'& CASSTRSSGELFF # )"#+ )%,# CVVSANNNARLMF #
!"#$ !%&'- CASSIRGSETQYF # )"#&'( )%,* CAVRLSNTGKLIF #
!"#$ !%&'* CASSPRSGGEQYF # )"#,'# )%$ CAASTPPGTGGF #
Clonotyes:11 )"#,'& )%-+ CAASIGTSYDKVIF #
Sequences:77 ## )"&* )%,* CAGDGSSNTGKLIF #
)"&* )%,* CAGASGSSNTGKLIF #
)"- )%(- CAGTPPPGGGADGLTF #
)"$'& )%#+ CALSTGGGNKLTF #
0"# )%&, CALGDRYNQGGKLIF #
VB family JB family CDR3 amino acid sequence # of copies Clonotyes:17
!"#$ !%&'& CASSIRSTGELFF ,# Sequences:68 !&
!"#$ !%&'* CASSIRSSYEQYF -
Clonotyes:2
Sequences:36 "!
VA family JA family CDR3 amino acid sequence # of copies
)"&/'& )%(& CILRDLTLGGSQGNLIF &&
)",/ )%(, CAVDPSYNNNDMRF #(
)"&* )%,* CAGTHGSSNTGKLIF .
)"#&', )%(& CAMSGHGGSQGNLIF &
)"&* )%(& CAGGGSQGNLIF &
Clonotyes:5
Sequences:48 %&
EBV-SN EBV-GLC Line VB Usage EBV-SN EBV-GLC Line VA Usage
EBV-SN Donor 1 EBV-SN Donor 1 
EBV-SN Donor 2
EBV-SN Donor 2
EBV-SN IAV-GIL Line VB Usage EBV-SN IAV-GIL Line VA Usage
EBV-SN Donor 1 EBV-SN Donor 1 
EBV-SN Donor 2 EBV-SN Donor 2
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  These cells also showed the potential to enter the mucosal epithelium where 
EBV infection initially occurs, thus potentially mediating resistance to infection 
upon exposure to EBV. 
These data strongly suggest that the characteristics of an individual’s TCR 
repertoire determines the outcome of disease when exposed to a new pathogen. 
In EBV-SP donors the IAV-GIL-specific response, while being restricted to the 
Vβ19 family, is quite diverse without dominant clones and maintains a xRSx 
CDR3B motif (Lehner et al., 1995; Lawson et al., 2001; Naumov et al., 2006; 
2008; Clute et al., 2010).  In contrast, the EBV-SN adults also maintained a Vβ19 
family restriction, but had an oligo-clonal response dominated by one clonotype 
with unique CDR3β motifs, which may have a better structure to recognize both 
antigens with higher avidity and contribute to a potent antiviral response.  
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Chapter IV: The use of humanized mice to study human EBV and IAV 
infections 
Many experimental models of infection are set up in a murine system.  
Mice are relatively inexpensive, they are genetically malleable, and there are 
many reagents available for use in their study.  However, mice are not always 
susceptible to human pathogens, and also findings in mice do not necessarily 
transfer over to be relevant to human disease.  Therefore, a model system is 
needed that has the clinically relevant human tissues and also the flexibility of an 
animal model.  By using a humanized mouse system one would potentially be 
able to conduct clinically relevant studies using pathogens that infect humans in 
a less restrictive environment without putting patients at risk.  
To conclusively show that heterologous immunity is actively protecting 
EBV-SN adults from the establishment of a productive EBV infection, one would 
have to deliberately expose an individual to the virus.  Clearly this is not an 
acceptable risk and could endanger the health of an individual.  A humanized 
mouse model could allow one to address this question.   
There have been many models of humanized mice, as was discussed 
earlier in the introduction (Fig1.6).  Here, we will be discussing mice that have 
been engrafted with human hematopoietic stem cells.  In particular we will be 
examining NOD SCID Il2rg-/- mice.  Three different models were used.  First was 
a straight NOD SCID Il2rg-/- (NSG) that was reconstituted with human CD34+ 
hematopoietic stem cells.  These mice engraft fairly well yet lack human MHC, 
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eliminating the possibility of detecting clinically relevant antigen specific T-cells. 
Additionally the T-cells that develop in these mice are not educated on a human 
MHC.  This would result in a human T-cell pool that is educated on murine MHC.  
This generates many complications.  
 The second model was a NOD SCID il2γ-/- HLA-A2 (NSG-HLA-A2/HHD) 
transgenic mouse that was reconstituted with human CD34+ hematopoietic stem 
cells.  These mice have a human MHC which will allow the human T-cells to be 
educated on human MHC, however there are no human tissues such as the 
human thymus which is important for T-cell development and appropriate positive 
and negative selection.  This model assumes that human T-cells can migrate to 
the murine thymus and develop properly.   
The third model was a NOD SCID il2γ-/- HLA-A2 transgenic mouse that 
was reconstituted with human CD34+ hematopoietic stem cells from the fetal 
liver and also was implanted with fetal thymus and fetal liver (BLT mouse).  
These mice show the most promise.  They have human tissues for the T-cells to 
be educated on and also human MHC molecules systemically for the T-cells to 
recognize. 
Since EBV is known to only infect human B-cells and mucosal epithelial 
cells we must first determine whether these mice can be infected with EBV.  
Since these mice are reconstituted with a human immune system, and should 
have human B-cells, we hypothesized that these mice would develop an infection 
and a functional immune response to the virus.  To determine the establishment 
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of infection we will be looking for an immune response.  This will also show that 
these mice are capable of mounting an immune response to EBV.  Additionally 
we also have to determine whether these mice can develop memory to IAV.  
There are mouse-adapted strains of influenza that should ensure the infectibility 
of these mice.  However, we need to determine whether they can mount an 
immune response to the virus, resolve the infection and also generate a memory 
response. 
A.  Humanized mice demonstrate pathology from viral infection by weight 
loss. 
One indicator of the establishment of an active infection and immune 
response is the onset of weight loss.  In all three murine models (NSG, NSG-
HLA-A2/HHD, and BLT) mice infected intraperitoneally (i.p.) with EBV lost weight 
as compared to uninfected controls (Fig 4.1).  In the NSG model a virus dose of 
either 100U of EBV supernatant in 100 µL or 400U of EBV supernatant in 400µL 
resulted in weight loss. Additionally, control mice that did not receive donor cells, 
but had been infected with EBV did not lose weight.  These mice would have 
lacked B-cells, the primary EBV reservoir.  These results suggest that an 
infection has occurred and the cells necessary for infection by EBV must be 
present.  EBV infection resulted in a slow progression of weight loss with only 
~10% reduction in weight.  IAV infection on the other hand, showed a rapid 
weight loss of ~20%.  These differences are probably attributable to the 
difference in viral and immune kinetics between the two viruses.  IAV is known to 
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replicate rapidly while little is known about the rate of EBV replication, particularly 
early in infection as patients with AIM are thought to have been exposed 4-6 
weeks before presentation with symptoms (Luzuriaga and Sullivan, 2010). 
B.  Splenomegaly and T-cell expansions in viral infection 
A classic hallmark of a viral infection is the expansion of lymphocytes in 
response to the infection.  EBV in particular shows an expansion of activated 
CD8 T-cells.  To determine whether our three models of humanized mice are 
producing an effective immune response to EBV infection we sought to examine 
the expansion of lymphocytes within these mice.   
Figure 4.2a shows that in NSG mice there was an onset of splenomegaly 
at 7 weeks post infection with EBV.  Note the increase in physical size of the 
spleen from a representative from each group of mice.  Next we wanted to 
determine which cell types were responsible for this increase in spleen size.  
Monoclonal antibodies directed against human and murine CD45 were used to 
identify human cells within the splenocytes.  Additionally monoclonal antibodies 
specific for CD3, CD4, CD8, and either CD19 or CD20 were used to distinguish 
T-cells from B-cells and helper T-cells from cytotoxic T-cells.  Frequencies were 
then compared to cell numbers to determine population specific cell numbers.  
As shown in Fig 4.2b mice that were infected with EBV showed an increase in 
human lymphocytes, particularly T-cells.  These data again suggest that these 
three humanized mouse models were successfully infected with EBV and were 
mounting an immune response to the infection. 
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In contrast to EBV infection in the humanized mice, IAV infection results in a 
lymphopenic state within the mice.  Figure 4.2e shows that there was a general 
decrease in human cells within mice infected with 50 PFU of IAV x31.  This also 
resulted in overall lower T-cell numbers in infected mice.  Although we lack viral 
titers to say for certain it appears these mice were unable to control the infection, 
as these mice had lost 20% of their weight by day 28 and appeared moribund, 
requiring euthanasia. 
C.  Increased frequency of activated CD8 T-cells during infection 
During an immune response T-cells get activated and develop effector 
functions in order to control infection.  While gaining these functions they also 
develop phenotypic markers, which enable one to identify their generation.  To 
this end we sought to identify effector functions and phenotypes in the T-cells 
within the humanized mice infected with EBV and IAV. 
In figure 4.3a we have gated on live human CD3+ cells and then looked 
at various effector markers.  In addition, we also examined the frequencies of 
CD4 and CD8 cells within the T-cell pool.  During an infection there is an 
increase in the frequency of CD8 cells as compared to CD4 cells, resulting in a 
skewed ratio of CD4 to CD8 T-cells.  As shown in figure 4.3a, during the EBV 
infection there was a shift to an increased frequency of CD8 cells as compared to 
CD4 cells at 8 weeks post infection.  Additionally, there was also an increased 
frequency of cells expressing the effector marker HLA-DR, an increased level of 
granzyme-B+ cells, and an increase of antigen-experienced cells as
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Figure 4.3.  Humanized mice show an increase in activated T-cells when 
infected. a) NSG mice either uninfected (left column) or infected with 100 U 
EBV IP (right column) at 7 weeks post infection.  Population gated on live 
human CD3+ cells.  CD8 cells show activation by inversion of CD4:CD8 ratios, 
increased expression of HLA-DR, granzyme B, and IFN  production when 
stimulated with PMA and Ionomycin. b) Day 28 post infection of BLT mice either 
uninfected or infected with 50 PFU IAV-x31 i.n.  The first and third graphs show 
the frequencies of CD8 cells gated on live human CD3+ cells from either the 
spleen or lung as indicated.  The second and fourth graphs show the 
frequencies of activated CD8 cells as measured by their lack of CD45RA 
expression within the spleen and lung as indicated. 
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measured by IFNγ staining in response to PMA stimulation.  Figure 4.3b shows 
an increase in the frequency of CD8 cells in IAV infected mice within the spleen 
and lung at day 28 post infection.  Additionally, there was an increase in the 
frequency of effector CD8 cells (CD45RA negative cells) within the spleen and 
lungs of IAV infected mice. 
To determine whether there was an active infection and evidence of 
immune-mediated pathology in these mice histological H and E staining was 
performed on histological sections of lungs and liver of these mice.  The top row 
of figure 4.4 shows a focal mononuclear lymphocytic infiltrate within the liver of 
EBV infected mice.  Mice infected with IAV also showed pathology.  Uninfected 
mice have clear open airways, whereas mice infected with IAV show enhanced 
pathology with pneumonic consolidation, hemorrhaging, and bronchiolization.  
These pathologies show us that there was an active infection with evidence of 
immune-mediated pathology occurring within these mice. 
D.  Summary 
From the evidence put forth in this thesis it appears that the humanized 
mice were indeed becoming infected with EBV and IAV.  The mice lost weight in 
response to infection, showed an increase in T-cell activation, and showed an 
increase in immune-mediated pathology.  While the IAV infected mice showed no 
increase in total cell numbers, presumably because of an uncontrolled infection, 
the EBV infected mice did show an increase in total cell number in the spleen.
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However, using our present models the quality of the response and similarity to 
human disease observed in the humanized mouse model are not optimum.  For 
the EBV infection it would be more desirable to see a larger CD8 T-cell response 
within the mice during infection.  For the IAV infection model it would be nice to 
see the mice be able to mount an immune response and clear the virus, but 
instead they succumb to the infection.  Thus, at this time we have not developed 
the IAV model to the point that we could test our hypothesis of IAV-GIL specific 
T-cell mediated protection from EBV infection.  These data are promising as the 
humanized mouse model is constantly improving.  Hopefully, with constant 
improvements being made there will be a model that will duplicate the human 
immune system more completely. 
94
Chapter V: Discussion 
Previous reports of heterologous immunity during human infections have 
focused on detrimental heterologous immunity, resulting from an altered immune 
response leading to increased and altered immunopathology (Mathew et al., 
1998; Clute et al., 2005; Urbani et al., 2005).  It is much easier to identify and 
study overt pathology than to examine the role of heterologous protective 
immunity in human infections, as a person is unlikely to come to medical 
attention when they have an asymptomatic infection.  However, many infections 
have variable outcomes ranging from asymptomatic to severe pathology, even 
death.  These severe outcomes provide hints as to where one could investigate 
the role of heterologous immunity during human infection.  Some specific 
examples include viral infections such as EBV where AIM develops in young 
adults who have large complex memory populations, while younger children are 
relatively asymptomatic (Clute et al., 2005).  Another example is the variation in 
severity of hepatitis in HCV infected patients, or the variation in outcome from 
mild fever to severe dengue hemorrhagic fever upon DENV infection (Mathew et 
al., 1998; Urbani et al., 2005).  Interestingly, these infections have had T-cell 
cross-reactive responses associated with their disease outcome.  However, in 
this thesis I demonstrated a high frequency of highly functional EBV cross-
reactive IAV-specific memory CD8 T-cells in EBV-SN individuals.  I believe this 
could be, for the first time, a description of beneficial protective heterologous 
immunity in humans, where heterologous immunity could prevent the 
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establishment of a productive EBV infection.  These results also suggest that 
memory CD8 T-cells may be able to mediate sterilizing immunity and that an 
individual’s unique TCR repertoire determines his or her fate. 
We have demonstrated that the IAV-GIL-specific memory T-cell pool in 
EBV-SN adults possesses a highly cross-reactive response that reacts against 
EBV lytic antigens.  These cross-reactive responses are shown by the ability to 
proliferate and secrete protective, antiviral cytokines such as IFNγ and MIP-1β in 
response to EBV lytic antigens. Additionally, CD8 T-cells from these EBV-SN 
adults are able to kill EBV-infected targets in a lytic antigen-dependent manner, 
and they also kill EBV lytic antigen peptide-loaded targets.  These cells, by 
expressing CD103, also showed the potential to enter the mucosal epithelium 
where EBV infection initially occurs, thus potentially mediating resistance to 
infection upon exposure to EBV. 
These data strongly suggest that the characteristic of an individual’s TCR 
repertoire determines the outcome of disease when exposed to a new pathogen. 
In EBV-SP donors the IAV-GIL-specific response, while being restricted to the 
Vβ19 family, is quite diverse, often including over 200 TCR Vβ clonotypes, 
without dominant clones and maintains a xRSx CDR3β motif (Lehner et al., 1995; 
Clute et al., 2005; Naumov et al., 2006; 2008; Clute et al., 2010).  In contrast, the 
EBV-SN adults also maintain a Vβ19 family restriction, but have an oligo-clonal 
response dominated by one clonotype with unique CDR3β motifs that may be 
better structured to recognize both antigens with higher avidity and contribute to 
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a potent antiviral response.  Additionally, the IAV-GIL specific TCR repertoire 
from AIM patients exhibits similar properties of the EBV-SP donors in that their 
IAV-GIL specific TCR repertoire is broad and very diverse (Clute et al., 2010).  
We believe it is this difference in the organization of the IAV-GIL memory CD8 T-
cell repertoire that is responsible for protecting these EBV-SN donors from the 
establishment of a productive EBV infection. 
This body of work demonstrates that heterologous immunity has the 
potential to protect individuals from infection, and it appears that it is the memory 
CD8 T-cell repertoire that is responsible for the protection.  If we could 
understand how to manipulate or control the memory CD8 T-cell repertoire, we 
could design vaccination strategies that would select for high avidity cross-
reactive memory CD8 T-cells that could protect an individual from an infection 
that he or she had never encountered.  However, great care would have to be 
taken, as a T-cell repertoire with high avidity to an antigen most likely would be 
narrow and oligo-clonal.  This would leave open the possibility for a viral escape 
mutant, which would render the vaccination strategy obsolete such as has been 
described (Cornberg et al., 2006a).  The study by Cornberg et. al. used the 
model of PV-immune mice subsequently challenged with LCMV.  This model 
results in the cross-reactive activation and expansion of memory CD8 T-cells 
specific for a relatively similar epitope (6 of 8 amino acids in common) shared 
between the two viruses, NP205.  Upon subsequent infection there was a drastic 
narrowing of the NP205 specific memory CD8 T-cell TCR repertoire.  PV immune 
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mice were infected with LCMV clone 13, a strain of LCMV that causes persistent 
infection, and 8 months after LCMV challenge, after being put under pressure by 
NP205 reactive memory cells, a viral escape mutant emerged that showed a 
mutation within the NP205 epitope.  Thus, an artificially altered repertoire could 
allow for viral escape mutants. 
From the work presented in this thesis we have shown that the IAV-GIL 
specific response within EBV-SN donors is quite distinctive when compared to 
that of EBV-SP donors.  Although the EBV-SN donor group included only five 
individuals, the demographic characteristics of this group does not appear to 
differ from our EBV-SP donors.  The EBV-SN donor’s geographical locations 
were also varied ranging from Europe to the southwestern United States, 
showing there is no environmental bias.  Thus, there are no obvious unintended 
biases within the donor pool that might suggest a genetic or geographic 
component to explain the differences in their EBV infection rate. 
The observation of an increased frequency of IAV-GIL specific memory 
cells cross-reactive with EBV was the primary indication that there might be a 
unique cross-reactive response in these individuals.  This nearly ten-fold 
increase in IAV-GIL reactive memory cells suggested that this population might 
have been reactivated on more than one occasion.  However, there is no obvious 
reason why they should have been reactivated any more than EBV-SP donors by 
exposure to IAV.  Perhaps, it is due to frequent and recent encounters with the 
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cross-reactive antigen, EBV, in the absence of a diverse EBV-specific memory 
population. 
These IAV-GIL reactive cells from EBV-SN donors can proliferate in 
response to EBV lytic antigens EBV-GLC and EBV-YVL (Fig 3.2).  These data 
imply that cross-reactive IAV-GIL memory cells from EBV-SN donors can 
become activated and divide so as to increase the size of the effector pool 
reactive against EBV antigens and go on to participate in an immune response to 
EBV infection.  Importantly, a truly naïve population of CD8 T-cells from cord 
blood does not exhibit this phenomenon of IAV-GIL specific expansion when 
cultured with EBV lytic antigens. 
These IAV-GIL cross-reactive CD8 T-cells from the EBV-SN donors can 
exert the effector function of cytokine production when stimulated with EBV 
antigens (Fig 3.4).  This is important in mediating protection from infection, as 
cytokine production is one of the most important aspects of T-cell effector 
function as cytokines manipulate the environment on which they act, rendering it 
inhospitable to virus. 
After we saw that these IAV-GIL cross-reactive cells could produce 
cytokines we next naturally wanted to know if they had a similar avidity for IAV-
GIL and EBV-GLC.  If these cross-reactive IAV-GIL memory cells from EBV-SN 
donors had a difference in functional avidity as compared to EBV-SP donors this 
may account for their unique abilities to expand and produce cytokines to the 
extent they did when grown in the presence of EBV antigens.  Remarkably, the 
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IAV-GIL cross-reactive cells from EBV-SN donors had a 1 and 2 log higher 
functional avidity to IAV-GIL and EBV-GLC, respectively than T-cells from EBV-
SP subjects.  This high functional avidity to EBV antigens may be what enables 
these cross-reactive IAV-GIL specific memory cells to mediate protection against 
EBV, and in fact mediate sterilizing immunity.  Interestingly, two independent 
groups using two different models have shown that TEM CD8 T-cells can mediate 
sterilizing protection.  One showed that TEM CD8 T-cells were generated after 
immunization of mice with radiation-attenuated Plasmodium sporozites and that 
these TEM populations correlated with protection from Plasmodium re-challenge, 
preventing a chronic infection, while Plasmodium specific Ig levels did not 
correlate with protection (Schmidt et al., 2010).  The second group showed that a 
SIV vaccine that includes rhesus cytomegalovirus (RhCMV) vectors established 
persistent, high frequency, SIV-specific TEM responses at potential sites of SIV 
replication in rhesus macaques and controlled SIV infection early after mucosal 
challenge before it establishes a chronic infection (Hansen et al., 2011).  Taken 
together these results suggest that T-cell vaccines against chronic infections 
such as EBV, malaria, and HIV may be feasible if designed correctly. 
Curiously though the IAV-GIL cross-reactive cells, despite having high 
functional avidity to EBV-GLC, do not seem to bind tetramer (Fig 3.5).  Since 
TCR/pMHC affinities are ratio of on rates and off rates, it may be that this 
interaction has a very high on rate, which could be responsible for the increased 
functional avidity, while an equally high or higher off rate could be responsible for 
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the lack of tetramer staining.  Interestingly, there have been other reports of 
antigen-specific T-cells that do not bind tetramer while being able to exert 
effector functions.  One group showed that CD8 T-cells reactive to a 
subdominant IAV epitope could not bind its tetramer when grown in the presence 
of whole virus infected stimulators, but with continued in vitro stimulation 
ultimately gained enhanced effector functions and low levels of tetramer staining 
(Spencer and Braciale, 2000).  A second group, using a complex biophysical 2D-
binding assay, demonstrated that a polyclonal MOG35-55 restricted CD4 T-cell 
population contained cells with a large range of affinities.  Even though only 8% 
of the population stained with tetramer, over 60% were reactive as measured by 
the 2D-binding assay and thus ~70% of the tetramer negative cells were antigen 
specific as measured by 2D-binding assay (Sabatino et al., 2011).  Thus, the 
tetramer, though a useful tool for defining antigen-specific T-cells, may under 
estimate some populations of T-cells, particularly cross-reactive T-cells as cross-
reactive T-cells may have a different affinity or avidity for its cross-reactive 
ligands.  Additionally a cross-reactive cell may see its alternate ligand in a 
different orientation than its cognate ligand.  Any of these may contribute to the 
different activating profiles of a cross-reactive T-cell. 
In order for CD8 T-cells to eliminate virus from the infected host they 
usually need to kill virally infected cells.  That is exactly what we see in the case 
of EBV-SN donors (Fig 3.6).  Cross-reactive cell lines generated by growth in the 
presence of either cognate IAV-GIL peptide or cross-reactive EBV-GLC peptide 
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were capable of killing EBV infected autologous BLCLs in a lytic antigen 
dependent manner.  Again this is a hallmark of CD8 T-cell effector function and 
could be what is mediating protection from infection. 
If an effector CD8 T-cell cannot make it to the site of infection than its 
abilities to kill virus-infected cells are wasted.  EBV-SN subjects’ IAV-GIL specific 
cells and cells that dimly stained with EBV-GLC tetramer ex vivo showed a 
higher level of CD103 staining as compared to EBV-SP donors. CD103 is an 
integrin molecule that has been shown to be necessary for entry into mucosal 
epithelial tissues, which is where EBV infection is thought to initiate.  We believe 
these dim EBV-GLC tetramer staining cells to be the IAV-GIL/EBV-GLC cross-
reactive CD8 T-cells because when both IAV-GIL and EBV-GLC tetramers are 
used to stain the CD8 T-cells, the dim EBV-GLC cells disappear, suggesting that 
there is a competition for the tetramers (Fig 5.1).  Presumably, these cells no 
longer stain with tetramer after in vitro stimulation due to the exposure to large 
amounts of antigen, which can cause down regulation of the TCR complex.  
These CD103 data imply that IAV-GIL specific cells from EBV-SN donors have 
the potential to enter the mucosal areas where infection initially occurs. 
Finally, we showed that the TCR repertoire within the IAV-GIL reactive cells is 
oligo-clonal.  This differs from EBV-SP donors who have a highly diverse TCR 
repertoire in response to IAV-GIL (Naumov et al., 2006).  This oligo-clonal 
structure may be a result of the high functional avidity to the cross-reactive 
antigens IAV-GIL and EBV-GLC that this population demonstrates, as this clone 
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may have out competed others to dominate the IAV-GIL specific memory pool.  
This is also the first evidence that the TCR repertoire to a certain antigen can 
determine disease outcome in humans.  If the cross-reactive IAV-GIL specific 
TCR repertoire from AIM patients are compared to that of EBV-SN donors it 
becomes clear that there is a difference in organization.  This may be why the 
AIM patients get sick and the EBV-SN donors show protection.  It may be that in 
AIM patients the broad TCR repertoire has a lower avidity to the EBV antigens.  
This could cause a broad CD8 T-cell expansion and recruitment, as these rather 
ineffective cross-reactive memory CD8 T-cells try to clear EBV, while EBV-SN 
donors with their oligo-clonal repertoire and high functional avidity are able to 
exert effector functions rapidly completely eliminating EBV before it is able to 
establish a chronic infection.  It is important to determine the composition of the 
T-cell TCR repertoire to decipher the differences that can account for disease 
progression, or in this case, the mediators of protective immunity.  If we could 
develop the technology to manipulate the T-cell repertoire we could use it to 
steer the repertoire away from a disease-mediating repertoire, such as during 
AIM, towards a more protective repertoire such as is seen within these EBV-SN 
adults. 
Another possibility that could explain the difference between protective 
heterologous immunity, as shown in this thesis, and detrimental heterologous 
immunity, as in AIM patients, may be that the IAV-GIL cross-reactive cells in the 
EBV-SN do not show a high expansion when encountering either cognate IAV-
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GIL antigen or cross-reactive EBV-GLC, -YVL antigens (Fig 3.2c).  Perhaps it is 
the ability to exert effector functions, which is seen more in TEM cells, over that of 
proliferation, which is seen more in TCM cells, that is important in mediating 
protection from infection.  Interestingly, a recent study demonstrated that this is 
indeed the case (Jiang et al., 2012).  In the study by Jiang et. al., mice with a 
localized VACV skin infection were surgically attached to uninfected mice to form 
parabiotic mice.  This allowed for circulating TCM cells to migrate to the uninfected 
mouse while resident TEM cells would remain in the tissues.  After eight weeks of 
attachment mice were surgically separated and allowed 2 weeks to recover.  
Mice were then given a skin VACV infection and viral loads within the skin were 
examined at 6, 14, and 26 days after infection.  Remarkably, the mice that 
received the primary skin infection retainined the resident TEM cells, showed 
significantly lower viral titers than the parabiotic mouse that had only the 
circulating TCM cells.  The data generated from this study show us that it is the 
TEM cell population that is primarily responsible for protection from reinfection at 
epithelial surfaces, and not TCM, which are most likely more important in 
combating systemic infections such as during LCMV infection. 
Because of the oligo-clonal nature of the α and β TCR repertoire within the 
IAV-GIL populations, which show high cross-reactive effector functions, we 
believe that the dominating clonotype encodes a highly cross-reactive TCR.  
From this study we may have defined the first cross-reactive T-cell receptor.  As 
a bonus this cross-reactive TCR may be protective in nature.  Potentially this 
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TCR, due to its high functional avidity, could be used to generate transgenic 
human T-cells for the treatment of EBV related diseases such as post transplant 
lympho-proliferative disorder (Bollard et al., 2003). 
The initial events in EBV infection are controversial.  It is generally 
accepted that EBV can infect both B-cells and also epithelial cells (Arvin et al., 
2007).  Data have shown that EBV generated from a B-cell, rather than from an 
epithelial cell, is better at infecting epithelial cells and that EBV generated from 
an epithelial cell, rather than from a B-cell is better at infecting B-cells (Borza and 
Hutt-Fletcher, 2002).  This was performed by isolating virus from either Akata-
Burrkit lymphoma cells (B-cell) or from AGS gastric carcinoma cells (epithelial 
cells).  These viruses were then used to infect either epithelial cells or B-cells.  
Viral infection was measured by western blot for B-cells or by colony 
transformation on epithelial cells.  It was found that this difference in tropism was 
being mediated by the difference in the viral attachment complex.  Virus with B-
cell tropism had trimeric attachment complex consisting of viral proteins gH-gL-
gp42, while virus with epithelial tropism had a dimeric complex consisting of gH-
gL.  This suggests that there is a cycle of EBV replication and infection between 
these two cell types.  This also suggests that the virus may need to ramp itself up 
to make the switch in tropism.  Since there is no in vivo experimental model to 
conclusively show the early events of infection we are left to speculate that 
perhaps EBV needs to first ramp up its B-cell tropism by initially infecting 
epithelial cells and then make the jump over to the B-cell pool.  Therefore, we 
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can say that B-cells are the primary reservoir of virus in persistently infected 
individuals and it is likely, although not certain, that the first cell infected in vivo is 
an epithelial cell (Arvin et al., 2007). 
When we consider all of the data we can begin to form a comprehensive 
model of what may be happening within these EBV-SN donors.  During an EBV 
infection the virus first comes and infects the tonsilar epithelial tissues (Arvin et 
al., 2007).  The virus then multiplies and accumulates, eventually managing to 
establish infection within the B-cell pool and go on to either cause disease in the 
form of AIM, or quietly slip into latency (Fig 5.2).  We propose that when EBV-SN 
donors are exposed to the virus their unique cross-reactive IAV-GIL memory 
CD8 T-cells can enter, or are already present in, the tonsillar epithelium and 
immediately kill the initially infected epithelial cells not allowing for the 
establishment of productive infection (fig 5.3). 
When one considers the fact that EBV infects over 95% of the population (Henle 
et al., 1969), and at any given time an infected individual is shedding large 
quantities of viral genome, (Hadinoto et al., 2009) the chances of never being 
exposed to the virus are slim, yet EBV-SN middle aged adults exist.  Due to the 
obvious ethical considerations of challenging an individual with virus, studying 
EBV-SN adults is a useful alternative to assess whether these donors possess 
unique cross-reactive responses that have properties that may protect them from 
EBV infection or from the establishment of productive infection. This observation 
of potentially protective cross-reactive responses in EBV-SN adults
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Figure 5.2. Route of EBV infection. The route of EBV infection begins with viralinfection of the tonsiallar epithelial cells (blue) where the virus amplifiesultimately to high enough levels to then infect the B-­‐cell pool (yellow) andestablish infection. Normally T-­‐cells (Red) are not yet specific to EBV antigensand do not participate until later in infection.
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Figure 5.3. Proposed model for protection from EBV infection. The route ofEBV infection begins with viral infection of the tonsiallar epithelial cells (blue);however, in EBV-­‐SN adults the cross-­‐reactive T-­‐cell pool (shaded red) is capableof killing infected cells not allowing the amplification of virus and theestablishment of productive infection within the B-­‐cell pool.
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leads to the questions of whether this is an example of protective heterologous 
immunity and how common is protective heterologous immunity in humans?  If 
cross-reactive responses are beneficial in humans they may easily go 
undetected.  It is much more likely that cross-reactive responses would be more 
likely detected in a pathological state, where they would be more evident.  
Interestingly, the HIV and HCV fields have noted that there appears to be natural 
resistance (as demonstrated by sero-negativity) to infection in certain high-risk 
groups that are continuously exposed to these viruses (Clerici et al., 1992; 
Langlade-Demoyen et al., 1994; Barcellini et al., 1995; Fowke et al., 1996; 
Mazzoli et al., 1997; Kamal et al., 2004; Roque-Cuéllar et al., 2011).  The HIV 
field has noted that a cohort of female sex workers from Kenya had a surprisingly 
high level of HIV sero-negativity considering the fact that they were a high-risk 
group.  Interestingly, if a worker left the trade for a time and then returned the 
worker would contract the virus.  This would suggest that the constant exposure 
to the virus was contributing to the immunity.  In fact, constant exposure may be 
the key, as the HCV studies mentioned above showed HCV specific responses in 
HCV sero-negative adults whose partner was HCV sero-positive.  Interestingly, 
cross-reactive epitopes have been identified in HCV and HIV sero-negative 
individuals (Wedemeyer et al., 2001; Acierno et al., 2003).  Perhaps this may be 
the mechanism by which these high-risk individuals are resisting infection.  
These findings would also suggest that if a cross-reactive memory T-cell 
population is protecting these individuals it requires continuous antigen exposure 
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to maintain a high enough frequency and to maintain a TEM phenotype so that it 
can immediately lyse virus infected cells. 
An alternative approach to further test our hypothesis of heterologous 
immunity mediated protection by cross-reactive IAV-GIL memory CD8 T-cells 
would be to perform a prospective study.  To do this we would enroll a large 
number of individuals into the study and follow them over a long period of time.  
A perfect sample population would be to enroll incoming college freshmen.  EBV 
sero-status would initially be evaluated at enrollment and monitored over their 
course of college studies.  This population is ideal as 75% of the individuals are 
EBV-SP, leaving 25% EBV-SN (Crawford et al., 2006a).  As these students are 
mixed together the EBV-SN students would become exposed to the virus.  For 
our study we would evaluate the same metrics used through out this thesis such 
as IAV-GIL frequencies ex vivo, the ability to respond to EBV antigens by 
cytokine production and cytotoxicity, and examine the IAV-GIL TCR repertoire 
structure.  We could then group the EBV-SN subjects by patterns of cross-
reactive strength and repertoire organization and potentially predict, based on 
data from this thesis, which individuals would sero-convert or remain EBV-SN. 
In human studies we are dependent on associations and correlations as 
demonstrated here.  The humanized mouse model would be an ideal alternative 
to directly address mechanistic questions.  It would offer the flexibility of a murine 
system with the relevance of a human immune system.  The humanized mouse 
system as it stands now allows for infection with the viruses, IAV and EBV, that 
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we need to use to study the protective role of IAV memory against EBV infection, 
but in our hands the immune response that is generated is not quite up to the 
physiological standards that need to be met.  For our studies we would need to 
be able to generate a CD8 T-cell epitope specific response.  Other groups have 
demonstrated EBV infection within the humanized mouse system using the same 
models we have used and generated an epitope specific response.  However, in 
their systems they used a much higher dose of virus, which most likely accounts 
for the difference (Melkus et al., 2006; Yajima et al., 2008; Shultz et al., 2010).  
Additionally other infection systems have been developed in these humanized 
mouse models including HIV, DENV, Malaria, and Salmonella typhi.  One aspect 
that will be difficult to overcome will be the establishment of IAV memory and to 
get antigen specific cells with a correct TCR repertoire, especially with the murine 
MHC still present in the mice.  As shown above the humanized mice were not 
able to control IAV and ultimately died even at low doses with a low virulence 
IAV-strain.  While not included in this thesis, prior immunization with the peptide, 
IAV-GIL in Freud’s complete adjuvant was not enough to protect the mice from 
IAV x31 challenge.  One possible reason that the mice used in these studies 
succumbed to IAV is that our particular HLA-A2 transgenic mouse strains are 
known to be poor presenters of HLA-A2 on their cell surfaces.  This may also 
help explain why we have difficulty developing HLA-A2 restricted responses.  On 
the other hand infection with an avirulent non-mouse adapted strain was 
attempted but that elicited no response suggesting there was no infection.  As of 
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now we cannot use the humanized mouse model of infection to test our 
hypothesis of IAV-GIL mediated protection from EBV infection.  However, there 
have been rapid advances in the field of humanized mice as of late.  One such 
advance is the development of NSG mice with the transgenic expression of 
membrane-bound human stem cell factor (SCF) which results in HSC 
engraftment without the need for irradiation (Brehm et al., 2012).  I am confident 
that soon we will be able to test out our theories in a humanized mouse model. 
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